On this page
Quick Reference
Overview and Recommendations
Background
- •Hyperthyroidism is a clinical syndrome of thyroid hormone excess resulting from sustained overproduction of triiodothyronine (T3) and thyroxine (T4) by the thyroid gland, most commonly due to Graves disease, toxic nodular goiter, or thyroiditis. It affects approximately 1.2% of the US population with a female-to-male ratio of 5:1, and its prevalence is rising in children.
- •Graves disease accounts for ~70% of hyperthyroidism cases in iodine-sufficient regions and is driven by stimulatory TSH-receptor autoantibodies (TRAb) that constitutively activate the TSH receptor on thyrocytes, independent of pituitary TSH. TRAb is detectable in >95% of cases and is the disease's specific biomarker.
- •Toxic nodular goiter (uninodular or multinodular) causes ~16% of cases, increasing with age and in iodine-deficient regions. Iodine supplementation in such populations can precipitate overt hyperthyroidism from pre-existing autonomous nodules via the Jod-Basedow phenomenon.
- •Thyroiditis (subacute, silent, postpartum, drug-induced) accounts for ~3% of hyperthyroidism and represents destructive release of stored hormone rather than increased synthesis, as evidenced by low or absent uptake on scintigraphy. It is typically self-limited.
- •Untreated hyperthyroidism increases the risk of atrial fibrillation (HR 1.42), hip fracture (HR 1.36), dementia (HR 1.39), and all-cause mortality (pooled RR 1.21). Even subclinical hyperthyroidism (suppressed TSH with normal T4/T3) carries significant long-term risks, including a 19% increase in cardiovascular mortality.
- •The four pillars of GDMT for Graves disease, methimazole, radioactive iodine, thyroidectomy, and beta-blockade, each target different points in the physiology: hormone synthesis, follicular destruction, surgical removal, and adrenergic symptom control. The choice depends on etiology, patient preference, pregnancy plans, and the presence of active Graves orbitopathy.
Evaluation
- •Suspect hyperthyroidism in any patient with weight loss despite increased appetite, palpitations, heat intolerance, and fatigue, the classic symptom triad. Symptoms typically develop over weeks to months in Graves disease, whereas thyroiditis often has a more abrupt onset over days.
- •Ask about family history of thyroid disease (sibling OR 7.5 for Graves), smoking (OR 1.9-3.3 for Graves; 5.7 for orbitopathy), recent iodine exposure (contrast media, amiodarone), immune checkpoint inhibitor therapy, and pregnancy status. In women of reproductive age, inquire about pregnancy plans and last menstrual period.
- •Examine for diffuse goiter (often with a bruit on auscultation in Graves), lid retraction, lid lag, proptosis, conjunctival injection, periorbital edema, tremor, hyperreflexia, and proximal muscle weakness. Auscultate the heart for irregular rhythm and assess for pretibial dermopathy or acropachy in Graves disease.
- •Order serum TSH as the initial screening test, a suppressed TSH (<0.4 mIU/L) has >99% sensitivity for overt hyperthyroidism. If TSH is suppressed, measure free T4 (FT4) and free T3 (FT3). Overt hyperthyroidism: suppressed TSH with elevated FT4 and/or FT3. Subclinical: suppressed TSH with normal FT4 and FT3.
- •Check for biotin interference, biotin, a common supplement, can cause falsely low TSH and falsely high FT4/FT3 on many immunoassay platforms. Patients should stop biotin for at least 3 days before testing.
- •Order TSH-receptor antibodies (TRAb) as the cornerstone of noninvasive diagnosis for Graves disease. A positive TRAb (second- or third-generation assay) has 97% sensitivity and 99% specificity, confirming Graves disease without need for further imaging in most cases.
- •If TRAb is negative, perform thyroid scintigraphy (technetium-99m pertechnetate or iodine-123) to distinguish toxic nodular goiter (focal/multifocal increased uptake) from thyroiditis (low or absent uptake). In pregnancy, scintigraphy is contraindicated; rely on clinical context and TRAb.
- •Order thyroid ultrasound with color Doppler if scintigraphy is equivocal or to assess nodule characteristics. In Graves disease, findings include diffuse hypoechogenicity and increased vascularity (peak systolic velocity >40 cm/s in the inferior thyroid artery).
- •Assess severity immediately: use the Burch-Wartofsky Point Scale (BWPS) for thyroid storm, score ≥45 indicates imminent storm, 25-44 impending storm. In thyroid storm, initiate therapy without waiting for lab confirmation if clinical suspicion is high.
- •Also consider: ECG for atrial fibrillation (present in 10-25% of overt cases), complete blood count (baseline before starting antithyroid drugs), liver enzymes (baseline for methimazole/PTU), and serum potassium if weakness or paralysis is present (suspect thyrotoxic periodic paralysis when K+ <3.0 mmol/L).
- •Diagnostic criteria for Graves disease: suppressed TSH, elevated FT4/FT3, positive TRAb, and diffuse goiter (often with orbitopathy). For toxic nodular goiter: suppressed TSH, elevated FT4/FT3, negative TRAb, and nodular goiter on imaging with focal uptake on scintigraphy.
- •Special populations: in pregnancy, use trimester-specific TSH reference intervals; gestational transient thyrotoxicosis (GTT) is common in the first trimester and does not require antithyroid drugs. In the elderly, TSH may be less suppressed and FT4 may be normal despite overt hyperthyroidism (apathetic hyperthyroidism).
- •Differential diagnosis includes factitious hyperthyroidism (exogenous thyroid hormone ingestion, low thyroglobulin, suppressed RAIU), TSH-secreting pituitary adenoma (elevated or inappropriately normal TSH, elevated alpha-subunit), and resistance to thyroid hormone (elevated T4/T3 with inappropriately normal/high TSH).
Management
- •For symptomatic control in all patients, initiate a beta-blocker: propranolol 20-40 mg PO every 6 hours or atenolol 25-50 mg PO daily. Titrate to heart rate <90-100 bpm. Continue until euthyroidism is achieved.
- •First-line antithyroid drug (ATD) for non-pregnant adults is methimazole (MMI) 10-30 mg PO once daily, depending on baseline FT4 elevation (10-15 mg for mild, 20-30 mg for moderate-to-severe). After achieving euthyroidism (typically 4-8 weeks), reduce to the lowest effective maintenance dose (5-10 mg daily).
- •Propylthiouracil (PTU) is reserved for the first trimester of pregnancy (due to lower teratogenicity risk than MMI), for patients with minor adverse reactions to MMI, and for thyroid storm. Dose: 100-150 mg PO every 8 hours (300-450 mg/day).
- •For Graves disease, offer ATD for 12-18 months; after withdrawal, remission occurs in 40-50% of patients. Higher remission rates are seen in those who become TRAb-negative and have small goiters. For relapse after a full course, offer definitive therapy (RAI or surgery) or long-term ATD (≥5 years).
- •Radioactive iodine (RAI) as definitive therapy: administer 131I as a fixed dose of 10-15 mCi (370-555 MBq) or a calculated dose based on thyroid uptake and volume. Goal is to induce hypothyroidism, managed with levothyroxine. Contraindicated in pregnancy, breastfeeding, and active moderate-to-severe Graves orbitopathy.
- •In patients with mild Graves orbitopathy or risk factors (smoking, high TRAb) undergoing RAI, administer prednisone prophylaxis: 0.2-0.5 mg/kg/day PO for 6-12 weeks, starting 1-3 days after RAI, to prevent progression of orbitopathy.
- •Total thyroidectomy is indicated when RAI is contraindicated, when Graves orbitopathy is active, when a large goiter causes compressive symptoms, or when coexistent thyroid cancer is suspected. Achieves immediate cure but carries risks of permanent hypoparathyroidism (1-2%) and recurrent laryngeal nerve injury (1-2%) in high-volume centers.
- •For thyroid storm (BWPS ≥25), initiate three drug classes simultaneously within the first hour: methimazole 20-30 mg PO or per NG tube, then 20 mg every 4-6 hours; propranolol 60-120 mg PO every 6 hours or 1-2 mg IV every 5-10 minutes; and iodine (SSKI 5 drops PO every 6 hours or Lugol's solution 8 drops every 6 hours) given 1 HOUR after the first ATD dose.
- •For thyrotoxic periodic paralysis (TPP): administer IV potassium chloride (KCl) at 10 mmol/hour until weakness resolves (mean dose 63±32 mmol for full recovery). Give propranolol 40-80 mg PO immediately, then 40-80 mg every 6 hours. Correct underlying hyperthyroidism with methimazole 20-40 mg PO daily.
- •For atrial fibrillation in hyperthyroidism: rate control with beta-blockers (propranolol or cardioselective agent if LVEF <40%); anticoagulate per CHA2DS2-VASc criteria until euthyroid for 4-6 weeks (DOACs preferred over warfarin unless valvular AF or hemodynamic instability). Defer electrical cardioversion until euthyroid unless hemodynamically unstable.
- •Monitoring during ATD therapy: check TSH, FT4, FT3 every 4-6 weeks until euthyroid, then every 3-6 months. Goal is normal TSH (0.4-4.0 mIU/L). Warn patients about agranulocytosis (risk ~0.3%): instruct to stop drug and seek immediate attention if fever or sore throat develops.
- •After RAI or thyroidectomy: start levothyroxine 1.6-1.8 mcg/kg/day when hypothyroidism develops. Check TSH 6-8 weeks after initiation, then annually once stable. Target TSH 0.5-2.5 mIU/L for most adults; higher target (1.0-4.0 mIU/L) may be appropriate for older patients or those with cardiac disease.
- •For toxic nodular goiter: definitive therapy (RAI or surgery) is preferred because spontaneous remission is rare. ATDs are not curative. Choice between RAI and surgery depends on goiter size, compressive symptoms, and patient preference.
- •What NOT to do: Do NOT administer iodine before an ATD in thyroid storm, iodine alone can worsen the storm. Do NOT use digoxin for rate control in hyperthyroid AF, it has reduced efficacy. Do NOT use block-and-replace ATD regimens, they increase drug exposure without improving remission. Do NOT perform electrical cardioversion for AF unless the patient remains in AF after 4-6 weeks of euthyroidism.
- •Treatment failure: For ATD failure (persistent hyperthyroidism after 6-12 months of adequate dosing or relapse after withdrawal), offer RAI or surgery. For RAI failure (persistent hyperthyroidism at 6 months), repeat RAI or proceed to surgery. For thyroid storm not improving after 24-48 hours of maximal medical therapy, add iopanoic acid (1 g PO then 0.5 g every 6 hours), initiate therapeutic plasma exchange, or consider urgent thyroidectomy.
- •When to refer: to endocrinology for complex cases (thyroid storm, pregnancy with Graves, pediatric hyperthyroidism, orbitopathy), to ophthalmology for moderate-to-severe Graves orbitopathy, to surgery for large goiter or compressive symptoms, and to cardiology for AF management or heart failure.
- •Discharge criteria after thyroid storm: euthyroid state (or near-euthyroid), heart rate <90 bpm off IV beta-blockers, no signs of organ failure. Transition to definitive management plan.
Board Review — High Yield
- •Burch-Wartofsky Point Scale (BWPS), A clinical scoring system (≥45 = thyroid storm) that guides emergency management; therapy should not wait for labs if suspicion is high.
- •TRAb (TSH-receptor antibody), The specific biomarker for Graves disease, positive in >95% of cases; its titer correlates with disease severity and predicts relapse after ATD withdrawal.
- •Methimazole embryopathy, Aplasia cutis and choanal atresia; avoid MMI in the first trimester; use PTU instead.
- •Jod-Basedow phenomenon, Iodine-induced hyperthyroidism in patients with pre-existing nodular goiter, seen after iodinated contrast or amiodarone.
- •Thyrotoxic periodic paralysis (TPP), Acute flaccid paralysis with hypokalemia (K+ <3.0 mmol/L), typically in young Asian men; treat with IV KCl 10 mmol/h and propranolol; correct underlying hyperthyroidism.
- •Subclinical hyperthyroidism, Suppressed TSH with normal FT4/FT3; not benign, increases risk of atrial fibrillation (HR 1.42), hip fracture (HR 1.36), and dementia (HR 1.39).
- •Graves orbitopathy, Smoking and RAI exacerbate it; steroid prophylaxis (prednisone 0.2-0.5 mg/kg/day for 6-12 weeks) is mandatory if RAI is used in patients with risk factors.
- •Amiodarone-induced thyrotoxicosis (AIT), Type 1 (iodine-induced, high RAI uptake) responds to thionamides, type 2 (destructive, low uptake) responds to glucocorticoids; mixed forms common.
- •Resistance to thyroid hormone (RTH), Elevated T4/T3 with inappropriately normal or high TSH; due to THRB mutation; treat with beta-blockers, not ATDs.
- •Therapeutic plasma exchange (TPE), Rapidly reduces circulating T4/T3 by 60-80% per exchange; indicated for refractory thyroid storm as a bridge to thyroidectomy.
Deep Dive — Evidence Details
Definition, Classification and Axis Nomenclature
- ▸Hyperthyroidism is defined by suppressed TSH and elevated thyroid hormones; severity is graded as overt (TSH <0.1 mIU/L) or subclinical (TSH 0.1-0.4 mIU/L with normal T4/T3).
- ▸Classification by etiology (primary, secondary, tertiary) and by specific disease (Graves, nodular, thyroiditis) determines treatment approach and prognosis.
- ▸Graves disease is the most common cause, characterized by TRAb positivity and often associated with orbitopathy; toxic nodular goiter increases in prevalence with age.
Hyperthyroidism is a clinical syndrome of thyroid hormone excess resulting from sustained overproduction of triiodothyronine (T3) and thyroxine (T4) by the thyroid gland, most commonly due to Graves disease, toxic nodular goiter, or thyroiditis [10]B2b[12]B2b. The term is often used interchangeably with thyrotoxicosis, but thyrotoxicosis is the broader state of thyroid hormone excess from any source, including exogenous ingestion; hyperthyroidism specifically denotes endogenous glandular overactivity [14]D5.
Also Called
- Thyrotoxicosis (when including exogenous causes)
- Graves disease (when autoimmune, the most common cause)
- Toxic goiter (nodular or diffuse)
- Basedow disease (historical eponym for Graves)
- Subclinical hyperthyroidism (mild biochemical elevation)
Definitions of Severity
Severity is graded by the degree of TSH suppression and the presence of elevated free T4 or T3. Overt hyperthyroidism is defined by a suppressed serum TSH <0.1 mIU/L with elevated free T4 and/or T3. Subclinical hyperthyroidism is defined by a low but detectable TSH (0.1 to 0.4 mIU/L) with normal free T4 and T3 [7]B2b[14]D5. Subclinical hyperthyroidism is not benign: it carries increased risks of (HR 1.42), (HR 1.36), and dementia (HR 1.39) over long-term follow-up [2]B2a[12]B2b.
Classification by Etiology
Hyperthyroidism is classified by the source of hormone overproduction. Primary hyperthyroidism (thyroid gland itself) accounts for >99% of cases. Secondary hyperthyroidism (pituitary TSH-secreting adenoma) and tertiary hyperthyroidism (hypothalamic TRH excess) are exceedingly rare [13]C4[21]C4. The table below lists the major etiologic subtypes.
| Type | Key Distinguishing Feature | Associated Marker/Subtype |
|---|---|---|
| Graves disease | Diffuse goiter, orbitopathy, pretibial dermopathy | TRAb positive; female predominance; onset 20-40 years [10]B2b |
| Multiple nodules on palpation or imaging; older age | No autoantibodies; often in iodine-deficient regions | |
| Toxic adenoma | Single hot nodule on scintigraphy | No autoantibodies; TSH receptor activating mutation [21]C4 |
| Thyroiditis (destructive) | Painful (subacute) or painless (silent, postpartum); low RAIU | Transient thyrotoxicosis; often viral or autoimmune |
| Factitious hyperthyroidism | Exogenous thyroid hormone ingestion | Low thyroglobulin; suppressed RAIU |
| Secondary hyperthyroidism | Pituitary adenoma; elevated TSH | TSH-secreting adenoma; rare [13]C4 |
| Tertiary hyperthyroidism | Hypothalamic lesion; elevated TRH | Extremely rare |
Clinical Significance
Hyperthyroidism affects approximately 1.2% of the US population, with a female-to-male ratio of 5:1 and rising incidence in children [10]B2b. Untreated hyperthyroidism increases the risk of atrial fibrillation, osteoporosis, and all-cause mortality [2]B2a[12]B2b. In pregnancy, maternal hyperthyroidism is associated with preterm birth, low birth weight, and child neurodevelopmental disorders [5]B2b. The condition also links to depression, anxiety, and metabolic dysfunction-associated fatty liver disease [7]B2b[16]B2b[20]B2b.
Pearl: Hyperthyroidism specifically denotes glandular overproduction; thyrotoxicosis is the broader term for any state of thyroid hormone excess, including exogenous ingestion [14]D5. The distinction between overt and subclinical hyperthyroidism is critical because subclinical disease carries significant long-term risks and may warrant treatment [2]B2a[12]B2b.
Axis Physiology, Pathophysiology and Biochemical Signature
- ▸The fundamental lesion in Graves disease is a loss of tolerance to the TSHR, yielding stimulatory autoantibodies (TRAb) that constitutively activate cAMP signaling, uncoupling thyroid hormone production from pituitary control [34, 54].
- ▸The biochemical pattern, suppressed TSH, elevated FT4/FT3, and positive TRAb, fingerprints the lesion as autoimmune hyperthyroidism; a negative TRAb with low TSH points toward toxic nodular goiter or thyroiditis [48, 52].
- ▸Activating TSHR mutations (germline or somatic) produce a non-autoimmune hyperthyroidism with identical biochemistry but absent TRAb, requiring genetic testing or scintigraphy for diagnosis [44].
The hypothalamic-pituitary-thyroid (HPT) axis is a classic negative-feedback loop. The hypothalamus secretes thyrotropin-releasing hormone (TRH), which stimulates the anterior pituitary to release thyroid-stimulating hormone (TSH). TSH then binds to the TSH receptor (TSHR) on thyroid follicular cells, driving synthesis and secretion of thyroxine (T4) and triiodothyronine (T3). Circulating T4 and T3, in turn, suppress TRH and TSH secretion at the hypothalamus and pituitary, respectively, thereby completing the regulatory circuit [48]D5[52]D5. T4 is the principal secretory product of the thyroid; T3, the more biologically active hormone, is largely generated peripherally via deiodination.
The Breakpoint: The TSH Receptor and Its Autoantibodies
The defining pathophysiologic lesion of Graves disease, the most common cause of hyperthyroidism, is a breakdown of tolerance to the TSHR. Autoreactive B cells produce stimulatory autoantibodies (TSH-receptor antibodies, TRAb) that bind the TSHR on thyrocytes and mimic the action of TSH, constitutively activating adenylyl cyclase and the downstream cAMP signaling cascade [34]D5[39]D5[54]D5. The result is unregulated thyroid hormone synthesis and follicular cell hyperplasia, independent of the usual pituitary governor. TRAb are detectable in >95% of patients with Graves disease and are the disease's specific biomarker [34]D5[48]D5.
TSHR is a seven-transmembrane domain G-protein-coupled receptor encoded on chromosome 14q31 [43]D5. The TSHR gene itself confers genetic susceptibility: polymorphisms in intron 1 are associated with Graves disease, though they do not cause [43]D5. Full-length TSHR undergoes complex post-translational cleavage, shedding the A-subunit into the circulation. This A-subunit is the primary autoantigen; immunizing mice with the human TSHR A-subunit (via adenovirus or Cre-loxP systems) recapitulates hyperthyroidism and orbital changes [41]D5. The Graves reactome is not monolithic, stimulatory, blocking, and neutral TSHR antibodies coexist in a given patient, but the stimulatory subset dominates the biochemical picture [39]D5.
Pathogenic Cascades: T-Cell Help, B-Cell Maturation, and Cytokine Milieu
Autoantibody production is T-cell dependent. Autoreactive CD4+ T cells that recognize TSHR epitopes provide help to B cells, driving class switching and affinity maturation [48]D5[54]D5. The immunologic trigger remains unknown, but several modifiers have been identified:
- Gut microbiome dysbiosis: The INDIGO multicenter study found that patients with active Graves disease have a significantly altered fecal microbiota, increased Actinobacteria, decreased Bacteroidetes, and a higher Firmicutes-to-Bacteroidetes ratio, compared with healthy controls [37]B3b. This dysbiosis normalizes after treatment, suggesting it is a consequence rather than a cause, but it may perpetuate immune activation.
- B-cell dysregulation: Patients with Graves disease have an expanded immature B lymphocyte compartment in the bone marrow, evidenced by elevated kappa-deleting recombination excision circles (KRECs) [47]B3b. Newly emigrated B cells are more numerous and may be more prone to autoreactivity.
- Cytokine pathways: The orbital fibroblast is a key target in Graves orbitopathy. TSHR and insulin-like growth factor-1 receptor (IGF-1R) are co-expressed on orbital fibroblasts; their cross-talk amplifies hyaluronan production, adipogenesis, and inflammation [49]D5[54]D5. Teprotumumab, an IGF-1R blocker, reverses this process, confirming the pathway's centrality [25]B2b.
Genetic Hyperthyroidism: Activating TSHR Mutations
A separate, non-autoimmune mechanism, activating mutations of the TSHR, causes genetic hyperthyroidism [44]D5. These gain-of-function mutations (most often in the transmembrane domain) lock the receptor in a constitutively active conformation, increasing cAMP even in the absence of ligand. The clinical phenotype depends on the mutation's timing and cellular distribution:
- Germline activating mutations cause familial nonautoimmune hyperthyroidism or sporadic congenital nonautoimmune hyperthyroidism, presenting in infancy or childhood with diffuse goiter, severe hyperthyroidism, and absent TRAb [44]D5.
- Somatic activating mutations (found in ~30-50% of solitary hyperfunctioning adenomas) produce a localized, clonal overgrowth of thyrocytes, giving the scintigraphic pattern of a "hot nodule" with suppressed uptake in the surrounding gland [44]D5[48]D5.
Biochemical Signature: The Lab Pattern That Fingerprints the Lesion
The HPT axis's tight feedback allows a single biochemical pattern to identify the axis break:
| Condition | TSH | FT4 | FT3 | TRAb | Interpretation |
|---|---|---|---|---|---|
| Graves disease | Suppressed (<0.01 mIU/L) | Elevated (or high-normal) | Elevated (often disproportionately high) | Positive (>1.5 IU/L) | Stimulatory autoantibody drives autonomous hormone production [34]D5 |
| Toxic nodular goiter | Suppressed | Elevated | Elevated | Negative | Somatic activating mutation(s) in nodules [48]D5 |
| Subacute (painful) thyroiditis | Suppressed | Elevated | Elevated (mild) | Negative | Destructive release of stored hormone, not increased synthesis [48]D5 |
| TSH-secreting pituitary adenoma | Elevated or inappropriately normal | Elevated | Elevated | Negative | Central defect, pituitary tumor autonomously secretes TSH [48]D5 |
| Gestational transient thyrotoxicosis (GTT) | Suppressed | Elevated | Elevated (mild) | Negative | hCG cross-reacts with TSHR; resolves spontaneously [26]B2b |
| Activating TSHR mutation | Suppressed | Elevated | Elevated | Negative | Germline or somatic gain-of-function mutation [44]D5 |
The key discriminators are TRAb (positive only in Graves) and the TSH level (suppressed in primary hyperthyroidism; elevated or inappropriately normal in central hyperthyroidism) [48]D5[52]D5.
In Graves disease, the FT3 is often elevated more than FT4 relative to the normal range, because the chronically stimulated thyrocyte prefers T3 secretion and tissue deiodinase activity is increased [34]D5[48]D5. This FT3-dominant pattern predicts more symptomatic disease and higher risk of relapse after antithyroid drug withdrawal [48]D5.
From Molecular Lesion to Systemic Manifestations
Each clinical consequence of hyperthyroidism traces back to the mechanism named above:
- Tachycardia and : Thyroid hormone binds nuclear thyroid hormone receptors in cardiomyocytes, increasing the transcription of rate-related ion channels (HCN2, HCN4) and accelerating sinoatrial node depolarization. Chronically high T3 also shortens the atrial refractory period, predisposing to re-entrant arrhythmias [30]D5[46]D5.
- Weight loss and increased metabolic rate: T3 upregulates uncoupling proteins (UCP1, UCP3) and mitochondrial biogenesis in adipose and skeletal muscle, dissipating proton gradient energy as heat rather than ATP [48]D5.
- Bone resorption and osteoporosis: TSH itself has an independent anti-osteoclastic effect via the TSHR on osteoclast precursors. In hyperthyroidism, suppressed TSH combined with direct T3-driven osteoclast activation synergistically accelerates bone turnover, reducing bone mineral density [35]D5.
- Graves orbitopathy: TSHR expression on orbital fibroblasts is upregulated in the disease state. Binding of TRAb (and potentially IGF-1R antibodies) stimulates these fibroblasts to produce hyaluronan, recruit CD4+ T cells, and undergo adipogenic differentiation, resulting in proptosis, periorbital edema, and extraocular muscle restriction [23]A1c[49]D5. Smoking and radioiodine therapy exacerbate this process by increasing orbital inflammation [23]A1c.
- : A sudden surge in circulating thyroid hormones (often triggered by infection, trauma, or surgery) overwhelms compensatory mechanisms, causing a hypermetabolic crisis with multiorgan failure [30]D5.
Pearl: The biochemical signature of hyperthyroidism, suppressed TSH, elevated FT4/FT3, and positive TRAb in Graves disease, is the direct readout of a broken HPT axis. Understanding the specific breakpoint (autoantibody, activating mutation, or destructive release) guides every subsequent decision, from choosing antithyroid drugs versus radioiodine to anticipating complications like orbitopathy or atrial fibrillation [34]D5[48]D5[52]D5.
| Condition | TSH | FT4 | FT3 | TRAb | Interpretation |
|---|---|---|---|---|---|
| Graves disease | Suppressed (<0.01 mIU/L) | Elevated (or high-normal) | Elevated (disproportionately high) | Positive (>1.5 IU/L) | Stimulatory autoantibody drives autonomous hormone production [34]D5 |
| Toxic nodular goiter | Suppressed | Elevated | Elevated | Negative | Somatic activating mutation(s) in nodules [48]D5 |
| Subacute (painful) thyroiditis | Suppressed | Elevated | Mildly elevated | Negative | Destructive release of stored hormone, not increased synthesis [48]D5 |
| TSH-secreting pituitary adenoma | Elevated or inappropriately normal | Elevated | Elevated | Negative | Central defect, pituitary tumor autonomously secretes TSH [48]D5 |
| Gestational transient thyrotoxicosis (GTT) | Suppressed | Elevated | Mildly elevated | Negative | hCG cross-reacts with TSHR; resolves spontaneously [26]B2b |
| Activating TSHR mutation (germline/somatic) | Suppressed | Elevated | Elevated | Negative | Germline or somatic gain-of-function mutation [44]D5 |
Epidemiology, Etiology and Risk Factors
- ▸Hyperthyroidism has a global prevalence of 0.2-1.3%, with Graves disease accounting for ~70% of cases in iodine-sufficient regions [48].
- ▸Risk factors include female sex, smoking (OR 1.9-3.3), family history (sibling OR 7.5), iodine excess or deficiency, coexisting autoimmune diseases, and drugs such as amiodarone and immune checkpoint inhibitors [23, 48, 60, 86].
- ▸Iodine status is a key geographic determinant: mild-to-moderate deficiency shifts the etiology toward toxic nodular goiter, while supplementation programs may transiently increase hyperthyroidism incidence via the Jod-Basedow phenomenon [80, 88].
The global prevalence of hyperthyroidism is 0.2-1.3%, making it one of the most common endocrine disorders [48]D5. In iodine-sufficient regions, the annual incidence of overt hyperthyroidism is 23 to 93 per 100,000 inhabitants, with a clear female predominance (female-to-male ratio 5:1 to 10:1) [48]D5[79]C4. The peak incidence occurs between the ages of 20 and 50 years, though it can present at any age [83]D5. Temporal trends show a stable incidence over recent decades in most populations, though changes in iodine fortification programs can shift the etiologic spectrum [80]D5.
Etiologic Categories
Hyperthyroidism is not a single disease; its etiologies cluster into four mechanistic categories that directly inform diagnostic workup and treatment selection:
Autoimmune (most common). Graves disease accounts for ~70% of all hyperthyroidism cases in iodine-sufficient areas [48]D5[83]D5. Autoimmune thyroiditis (Hashimoto's) only rarely causes a transient hyperthyroid phase ("hashitoxicosis") early in its natural history.
Neoplastic (nodular autonomy). Toxic nodular goiter (uninodular or multinodular) causes ~16% of cases, and its prevalence increases with age and in regions of mild-to-moderate iodine deficiency [48]D5[80]D5. Iodine supplementation in such populations can precipitate overt hyperthyroidism from pre-existing autonomous nodules (Jod-Basedow phenomenon) [80]D5[88]D5.
Iatrogenic and drug-induced. This category accounts for ~9% of cases [48]D5. Major culprits include:
- : can cause both iodine-induced hyperthyroidism (type 1) and destructive thyroiditis (type 2) [83]D5.
- Immune checkpoint inhibitors (ICIs): a meta-analysis of 69 RCTs found ICI therapy increases the risk of hyperthyroidism with an incidence of 2.9% (95% CI 2.2-3.7%) for any grade and 0.3% (95% CI 0.1-0.5%) for grades 3-5 [60]A1a. Combination ICI therapy (e.g., anti-PD-1 + anti-CTLA-4) carries a higher risk than monotherapy [60]A1a.
- Tyrosine kinase inhibitors (TKIs): can cause destructive thyroiditis [48]D5.
- Lithium: long-term use increases the risk of hyperthyroidism; in a large retrospective analysis, lithium-treated patients had a higher incidence of thyrotoxicosis compared to controls (HR 2.31, 95% CI 1.80-2.97) [85]C4.
- Excess iodine load: from iodinated contrast media, especially in patients with underlying nodular goiter or subclinical Graves disease [66]B2c[88]D5.
Thyroiditis (destructive). Subacute granulomatous (de Quervain) thyroiditis accounts for ~3% of hyperthyroidism cases [48]D5. It is often preceded by an upper respiratory tract infection, and viral or post-viral etiology is presumed [83]D5.
Risk Factors
| Risk Factor | Association (OR/RR) | Evidence Level |
|---|---|---|
| Female sex | RR ~5-10 vs. males | 2a [48]D5[83]D5 |
| Family history | Sibling OR 7.5 for Graves disease | 2b [86]B2b |
| Smoking | OR 1.9-3.3 for Graves disease; 5.7 for Graves orbitopathy | 1c [23]A1c[48]D5 |
| Iodine deficiency (mild-moderate) | Increases toxic nodular goiter prevalence | 2c [80]D5 |
| Excess iodine intake | OR ~1.5-2 for developing hyperthyroidism in at-risk populations | 2c [88]D5 |
| TPOAb positivity | HR 2.8 (95% CI 1.8-4.3) for incident hyperthyroidism | 2b [65]B2a |
| Postpartum period | RR 2-5 for new-onset Graves disease | 2b [84]D5 |
| Stressful life events | OR ~1.5-2.0 (modest association) | 3b [48]D5 |
| Concurrent autoimmune disease | Celiac disease prevalence in ATD: 1.6% (95% CI 1.3-2.0%) [67]B2c; Type 1 diabetes: 7.8% have autoimmune thyroid disease [76]B2b | 2c [67]B2c[71]B2c[76]B2b |
Autoimmune Clustering
Graves disease commonly clusters with other autoimmune disorders. The prevalence of celiac disease in patients with autoimmune thyroid disease (ATD) is 1.6% (95% CI 1.3-2.0%), approximately 5-fold higher than in the general population [67]B2c. Among patients with type 1 diabetes, 22.8% have an additional autoimmune disease, with autoimmune thyroid disease being the most common (pooled prevalence 7.8% for hypothyroidism and 0.4% for hyperthyroidism) [71]B2c[76]B2b. Familial aggregation is strong: siblings of a Graves disease proband have an OR of 7.5 (95% CI 5.9-9.5) for developing the disease [86]B2b.
Iodine Status and Geographic Variation
Iodine intake is a critical environmental determinant. In areas of iodine sufficiency, Graves disease is the predominant cause; in mild-to-moderate iodine deficiency, toxic nodular goiter becomes more prevalent [80]D5. The introduction of universal salt iodization programs initially increases the incidence of hyperthyroidism (due to Jod-Basedow phenomenon in nodular goiters), but this typically stabilizes over 5-10 years [80]D5[83]D5. In China, mandatory salt iodization achieved a median urinary iodine concentration of 177.9 μg/L and a hyperthyroidism prevalence of 0.78% for overt disease and 0.44% for subclinical disease [78]C4. The risk of iodine-induced hyperthyroidism after iodinated contrast media is 0.5-1.0% in unselected populations, but higher in those with pre-existing nodular goiter or subclinical Graves disease [66]B2c.
Seasonal Variation
Subacute granulomatous thyroiditis shows a seasonal pattern, with most cases occurring late summer to fall, often weeks after a viral upper respiratory infection [83]D5. A preceding illness is reported in ~50-67% of cases [48]D5. No clear seasonal pattern exists for Graves disease.
Drug-Induced Hyperthyroidism: Key Agents
- Amiodarone: type 1 (iodine-induced) and type 2 (destructive) amiodarone-induced thyrotoxicosis (AIT) occur in 2-12% of treated patients, with incidence dependent on iodine intake [88]D5.
- Immune checkpoint inhibitors: a meta-analysis of 27 clinical trials in nasopharyngeal carcinoma reported any-grade hyperthyroidism incidence of 4.3% (95% CI 2.5-6.8%) with anti-PD-1 agents [87]A1a. Combination ICI therapy (anti-PD-1 + anti-CTLA-4) carries a higher risk than monotherapy [60]A1a.
- (T3) or overdose: factitious or iatrogenic thyrotoxicosis [84]D5.
Note on Vaccine-Related Risk: No robust evidence links routine vaccinations (including SARS-CoV-2 vaccines) to an increased risk of incident hyperthyroidism beyond the general background rate. Transient thyroiditis has been reported in rare post-vaccination case reports, but population-level data do not demonstrate a causative association [48]D5.
Pearl: The etiologic spectrum of hyperthyroidism shifts with iodine intake and age, Graves disease dominates in young women in iodine-sufficient areas, while toxic nodular goiter becomes more common in older adults and in iodine-deficient populations [48]D5[80]D5[84]D5.
| Risk Factor | Association (OR/RR) | Evidence Level |
|---|---|---|
| Female sex | RR ~5-10 vs. males | 2a [48]D5[83]D5 |
| Family history | Sibling OR 7.5 for Graves disease | 2b [86]B2b |
| Smoking | OR 1.9-3.3 for Graves disease; 5.7 for Graves orbitopathy | 1c [23]A1c[48]D5 |
| Iodine deficiency (mild-moderate) | Increases toxic nodular goiter prevalence | 2c [80]D5 |
| Excess iodine intake | OR ~1.5-2 in at-risk populations | 2c [88]D5 |
| TPOAb positivity | HR 2.8 (95% CI 1.8-4.3) | 2b [65]B2a |
| Postpartum period | RR 2-5 for new-onset Graves disease | 2b [84]D5 |
| Concurrent celiac disease | Prevalence 1.6% in ATD (5-fold increase) | 2c [67]B2c |
| Type 1 diabetes | 7.8% have autoimmune thyroid disease | 2c [71]B2c[76]B2b |
| Lithium therapy | HR 2.31 (95% CI 1.80-2.97) | 4 [85]C4 |
| Immune checkpoint inhibitors | Any-grade incidence 2.9% (95% CI 2.2-3.7%) | 1a [60]A1a |
Clinical Presentation
- ▸Classic triad of weight loss, palpitations, and heat intolerance is present in most patients, but older adults may present with anorexia and atrial fibrillation.
- ▸Thyroid eye disease occurs in up to 50% of Graves patients; optic neuropathy requires urgent intervention.
- ▸Thyrotoxic periodic paralysis presents with hypokalemic flaccid paralysis, often in Asian men, and requires cautious potassium replacement.
Weight loss despite increased appetite, palpitations, and heat intolerance form the classic triad that brings most patients to clinical attention. Symptoms typically develop over weeks to months in Graves disease, whereas thyroiditis often presents with a more abrupt onset over days [30]D5. The severity ranges from mild anxiety and tremor to life-threatening , with progression influenced by age, sex, and underlying etiology [30]D5[34]D5.
Presenting Symptoms
Palpitations, fatigue, and heat intolerance are reported by over 80% of patients with overt hyperthyroidism [34]D5. Increased appetite with weight loss is characteristic, though some patients, particularly older adults, may experience anorexia and weight gain [30]D5. Hyperdefecation or diarrhea, menstrual irregularities (oligomenorrhea or amenorrhea), and proximal muscle weakness are common. In Graves disease, goiter is present in most patients, often with a bruit on auscultation [34]D5. Patients with (MNG) may present with compressive symptoms such as dysphagia or dyspnea, especially when the goiter is large [108]D5.
Neurological and Ocular Findings
Tremor, hyperreflexia, and proximal myopathy are hallmark neuromuscular signs. Thyrotoxic (TPP) presents with sudden-onset flaccid paralysis, typically in the lower extremities, accompanied by hypokalemia (mean serum K+ 2.1 ± 0.2 mmol/L) [106]D5[109]B2b. Attacks are often precipitated by high-carbohydrate meals or exercise [110]B2b.
Thyroid eye disease (TED) occurs in up to 50% of patients with Graves disease and is characterized by lid retraction, lid lag, proptosis, conjunctival injection, chemosis, and periorbital edema [49]D5[82]D5. Diplopia and optic neuropathy are sight-threatening complications; optic neuropathy requires urgent intervention [49]D5. TED is mild in 77% of cases, moderate-to-severe in 22%, and sight-threatening in 1% [49]D5.
Phenotypic Variants
| Variant | Key Features | Frequency |
|---|---|---|
| Graves disease | Diffuse goiter, orbitopathy, dermopathy, TRAb positive | Most common cause (60-80%) [34]D5 |
| Toxic MNG | Nodular goiter, older age, no orbitopathy | Common in iodine-deficient regions [108]D5 |
| Painful thyroid, transient hyperthyroidism, low RAIU | 5-10% of hyperthyroidism [117]C4 | |
| Hyperthyroid phase (30%) then hypothyroid (48%) | 5.4% of postpartum women [98]D5 | |
| TSHoma | Central hyperthyroidism, goiter, visual field defects, elevated TSH | Rare (<1%) [68]C4[113]C4 |
| Thyrotoxic periodic paralysis | Episodic paralysis, hypokalemia, male Asian | 2% of Asian hyperthyroid men [106]D5 |
| Thyroid storm | Fever >38°C, tachycardia >140 bpm, altered mental status, GI symptoms | 1-2% of hospitalized hyperthyroid patients [30]D5 |
| -induced thyrotoxicosis | Type 1 (iodine-induced) or type 2 (destructive) | 3% of amiodarone users [101]C4 |
| ICI-induced thyroiditis | Transient thyrotoxicosis followed by hypothyroidism | 10-20% of ICI-treated patients [107]B2b |
| Congenital hyperthyroidism | Activating TSHR mutation, , failure to thrive | Rare [104]C4 |
| Resistance to thyroid hormone | Elevated TH with inappropriate TSH, variable symptoms | Rare [102]C4 |
| McCune-Albright syndrome | Hyperthyroidism with fibrous dysplasia, café-au-lait spots | Rare [116]C4 |
| Carney complex | Hyperthyroidism with spotty pigmentation, cardiac myxoma | Rare [114]C4 |
Red Flags
Thyroid storm is a medical emergency defined by fever >38°C, tachycardia >140 bpm, altered mental status, and symptoms (nausea, vomiting, diarrhea) [30]D5. Precipitants include infection, surgery, trauma, or radioactive iodine therapy. TPP requires immediate potassium supplementation (IV KCl 10 mmol/h) to prevent arrhythmias; serum K+ < 3.0 mmol/L is critical [109]B2b. TED with optic neuropathy presents with visual loss, color desaturation, and afferent pupillary defect; urgent orbital decompression may be needed [49]D5. Severe cholestasis (jaundice, pruritus) can be the presenting feature of Graves disease and resolves with antithyroid therapy [100]C4. Cardiac complications include , heart failure, and myocardial infarction with AV block [30]D5[118]C4.
Atypical Presentations
Hyperthyroidism may present with isolated cholestatic jaundice without typical thyrotoxic symptoms [100]C4. Acute inferior myocardial infarction with third-degree AV block has been reported as the first manifestation [118]C4. Propylthiouracil can cause interstitial pneumonia, presenting with cough and dyspnea [101]C4. Painless subacute thyroiditis after may manifest only as reduced exercise capacity [117]C4. In Carney complex, hyperthyroidism coexists with spotty skin pigmentation and [114]C4. McCune-Albright syndrome may present with and kidney failure alongside hyperthyroidism [116]C4.
Pearl: The clinical spectrum of hyperthyroidism ranges from subtle neuropsychiatric changes to life-threatening storm; recognizing atypical presentations such as cholestasis, periodic paralysis, or cardiac ischemia is critical for timely diagnosis and [30]D5[100]C4[106]D5.
Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
- ▸Biochemical confirmation requires suppressed TSH with elevated FT4/FT3; subclinical hyperthyroidism has normal FT4/FT3.
- ▸TRAb is the most specific noninvasive test for Graves disease and should be measured in all cases of overt hyperthyroidism.
- ▸Thyroid scintigraphy is reserved for TRAb-negative cases to distinguish toxic nodular goiter from thyroiditis.
The diagnosis of hyperthyroidism rests on a two-step process: biochemical confirmation of thyroid hormone excess, followed by etiological differentiation to guide therapy [48]D5[52]D5. A clinician who skips the second step risks mismanaging a patient with thyroiditis as if they had Graves disease, or vice versa. This section provides the diagnostic framework from first lab to final localization.
Biochemical Confirmation: The TSH-FT4-FT3 Triad
Serum thyrotropin (TSH) is the single best screening test for hyperthyroidism. A suppressed TSH (<0.4 mIU/L) has >99% sensitivity for overt hyperthyroidism [48]D5[52]D5. When TSH is suppressed, the next step is measurement of free thyroxine (FT4) and free triiodothyronine (FT3). Overt hyperthyroidism is defined by a suppressed TSH with elevated FT4 and/or FT3. Subclinical hyperthyroidism is defined by a suppressed TSH with normal FT4 and FT3 [61]A1c.
Biotin interference is a critical preanalytical pitfall. Biotin, a common over-the-counter supplement, can cause falsely low TSH and falsely high FT4 and FT3 on many immunoassay platforms. Patients should discontinue biotin for at least 3 days before thyroid function testing [132]B2b. The effect is dose-dependent and can persist for days after cessation.
| Test | Overt Hyperthyroidism | Subclinical Hyperthyroidism | Nonthyroidal Illness |
|---|---|---|---|
| TSH | Suppressed (<0.4 mIU/L) | Suppressed (<0.4 mIU/L) | Variable (often low) |
| FT4 | Elevated | Normal | Low or normal |
| FT3 | Elevated | Normal | Low |
Table 1: Biochemical patterns in hyperthyroidism and nonthyroidal illness [48]D5[52]D5.
Etiological Differentiation: TRAb and Imaging
Once biochemical hyperthyroidism is confirmed, the cause must be identified. The most common etiologies are Graves disease (70%), toxic nodular goiter (16%), and thyroiditis (3%) [48]D5.
TSH-receptor antibodies (TRAb) are the cornerstone of noninvasive diagnosis of Graves disease. TRAb has a sensitivity of 97% and specificity of 99% for Graves disease when measured by second- or third-generation assays [34]D5[48]D5. A positive TRAb establishes the diagnosis of Graves disease without need for further imaging in most cases [61]A1c. Thyroid peroxidase antibodies (TPOAb) are often positive in Graves disease but are not specific; they are more useful in diagnosing .
Thyroid ultrasound with color Doppler is a sensitive imaging tool for Graves disease. Typical findings include diffuse hypoechogenicity and increased vascularity, often quantified by peak systolic velocity in the inferior thyroid artery (>40 cm/s) [48]D5. Ultrasound also identifies coexisting nodules that may require further evaluation.
Radionuclide thyroid scintigraphy (using technetium-99m pertechnetate or iodine-123) is reserved for TRAb-negative cases to distinguish toxic nodular goiter from thyroiditis [48]D5[61]A1c. In Graves disease, uptake is diffusely increased. In toxic nodular goiter, uptake is focal or multifocal with suppression of extranodular tissue. In thyroiditis, uptake is low or absent.
| Condition | TRAb | Scintigraphy Uptake | Ultrasound Features |
|---|---|---|---|
| Graves disease | Positive | Diffusely increased | Diffuse hypoechogenicity, increased vascularity |
| Toxic nodular goiter | Negative | Focal/multifocal increased | Nodule(s) with increased vascularity |
| Thyroiditis | Negative | Low or absent | Heterogeneous, decreased vascularity |
Table 2: Etiological differentiation of hyperthyroidism [48]D5[61]A1c.
Dynamic Testing (When Needed)
Dynamic testing is rarely required in modern practice but remains useful in select scenarios. The T3 suppression test (administration of followed by repeat scintigraphy) can confirm autonomy in equivocal cases but is seldom used due to safety concerns [61]A1c. The TRH stimulation test (measurement of TSH after intravenous TRH) can differentiate pituitary causes of hyperthyroidism (TSHoma) from ; a flat response suggests TSHoma, while an exaggerated response suggests resistance [68]C4. In practice, MRI of the pituitary and measurement of the alpha-subunit to TSH molar ratio are preferred for TSHoma diagnosis [68]C4.
Diagnostic Algorithm
Step 1: Screen with TSH. If TSH is suppressed (<0.4 mIU/L), proceed to Step 2.
Step 2: Confirm with FT4 and FT3. If FT4 and/or FT3 are elevated, overt hyperthyroidism is present. If both are normal, subclinical hyperthyroidism is present.
Step 3: Measure TRAb. If TRAb is positive, Graves disease is confirmed. No further imaging is needed unless there is suspicion of coexisting nodules or atypical features [61]A1c.
Step 4: If TRAb is negative, perform thyroid scintigraphy. High uptake indicates toxic nodular goiter (single or multiple nodules). Low or absent uptake indicates thyroiditis (subacute, silent, or drug-induced).
Step 5: Consider special populations. In pregnancy, use trimester-specific TSH reference intervals; gestational transient thyrotoxicosis (GTT) is common in the first trimester and does not require antithyroid drugs [129]B2b[136]D5. In the elderly, TSH may be less suppressed and FT4 may be normal despite overt hyperthyroidism [131]D5. In patients on , distinguish type 1 (high uptake on scintigraphy) from type 2 (low uptake) [48]D5.
Special Considerations
Pregnancy: The diagnosis of hyperthyroidism in pregnancy requires trimester-specific TSH reference intervals. A fixed upper limit of 4.0 mIU/L for TSH leads to overdiagnosis [129]B2b. GTT, associated with hyperemesis gravidarum, is characterized by suppressed TSH, elevated FT4, negative TRAb, and low scintigraphy uptake (though scintigraphy is contraindicated in pregnancy) [26]B2b[136]D5. Graves disease in pregnancy is confirmed by positive TRAb [22]A1c[119]A1c.
Elderly: Overt hyperthyroidism in older adults may present with atypical symptoms (apathetic hyperthyroidism). TSH is suppressed but FT4 may be normal; FT3 is often low due to reduced peripheral conversion [131]D5. Scintigraphy is helpful if TRAb is negative.
Amiodarone-induced thyrotoxicosis (AIT): Type 1 AIT occurs in abnormal thyroid glands and shows increased uptake on scintigraphy; type 2 AIT is a destructive thyroiditis with low uptake [48]D5. TRAb is usually negative in both types.
Biotin interference: As noted, biotin can cause falsely low TSH and falsely high FT4/FT3. Patients should stop biotin for at least 3 days before testing [132]B2b.
Controversies and Guideline Disagreement
| Question | ATA 2016 [61]A1c | ESE 2023 [48]D5 | EUGOGO 2021 [23]A1c |
|---|---|---|---|
| First-line test after biochemical confirmation | TRAb | TRAb | TRAb |
| Role of scintigraphy | For TRAb-negative cases | For TRAb-negative cases | For TRAb-negative cases |
| Routine ultrasound in Graves disease | Not recommended for diagnosis | May be used to assess vascularity | Recommended to assess thyroid volume and nodules |
Table 3: Guideline comparisons on diagnostic approach.
The major controversy is the role of routine thyroid ultrasound in Graves disease. ATA 2016 does not recommend it for diagnosis, while many European clinicians use it to assess vascularity and to screen for nodules that may require biopsy [48]D5[61]A1c. There is consensus that TRAb is the first-line test after biochemical confirmation and that scintigraphy is reserved for TRAb-negative cases.
Pearl: The diagnostic workup of hyperthyroidism follows a sequential approach: confirm biochemical excess with TSH and FT4/FT3, then identify the cause using TRAb and, if needed, scintigraphy. TRAb positivity alone establishes Graves disease without need for imaging in most cases [48]D5[61]A1c.
Severity, Staging and Risk Stratification
- ▸Biochemical severity (subclinical vs. overt) and clinical complications (atrial fibrillation, heart failure) define risk tiers that select treatment intensity and surveillance interval.
- ▸TRAb titer and thyroid volume predict relapse in Graves disease and risk of Graves orbitopathy; etiology-specific stratification (e.g., amiodarone-induced type 1 vs. type 2) alters management.
- ▸Special populations (pregnancy, children, elderly) require adjusted thresholds for severity and treatment goals to minimize adverse outcomes.
Once the diagnosis of hyperthyroidism is confirmed and its etiology established, the next step is to assign a severity grade and risk tier that directly selects treatment intensity, surveillance interval, and, for patients with Graves orbitopathy (GO), surgical urgency. Unlike cancer staging, hyperthyroidism uses a composite of biochemical, clinical, and etiologic factors to stratify risk. This section converts the confirmed diagnosis into actionable tiers.
Biochemical Severity Grading
Biochemical severity is the first layer. Subclinical hyperthyroidism is defined by a suppressed serum TSH (<0.1 mIU/L) with normal free T4 (FT4) and free T3 (FT3) levels [61]A1c. Overt hyperthyroidism requires suppressed TSH plus elevated FT4 and/or FT3 [61]A1c. Within overt disease, further gradation is useful: mild overt (FT4 elevated but FT3 normal), moderate overt (both FT4 and FT3 elevated), and severe overt (FT4 >2× upper limit of normal and FT3 >2× upper limit of normal, often with very low TSH <0.01 mIU/L). The risk of progression from subclinical to overt hyperthyroidism is approximately 1-2% per year [48]D5. Even subclinical disease carries clinical significance: a meta-analysis of 17 cohort studies found that subclinical hyperthyroidism increased the risk of cardiovascular events (RR 1.19, 95% CI 1.10-1.30) and cardiovascular mortality (RR 1.24, 95% CI 1.06-1.45) [149]A1a. The absolute risk increase depends on baseline cardiovascular risk; NNT to prevent one cardiovascular event is not calculable from the reported aggregate data but is estimated to be >100 in low-risk populations [149]A1a.
Clinical Severity and Complication Risk
Clinical severity integrates symptoms and signs. Mild: tachycardia (heart rate 90-110 bpm), tremor, mild weight loss, heat intolerance. Moderate: palpitations, fatigue, proximal muscle weakness, frequent bowel movements. Severe: (especially in patients >60 years), heart failure, (see Section 7). The presence of atrial fibrillation or heart failure automatically upgrades the risk tier to high regardless of biochemical values [46]D5. Hyperthyroidism increases thrombin generation and activates the contact system, raising thrombotic risk even in the absence of atrial fibrillation [156]B3b. Electrocardiographic changes include prolonged QTc interval, which correlates with FT4 levels and may predispose to [164]A1a.
Etiology-Specific Risk Stratification
Graves disease: The titer of TSH-receptor antibodies (TRAb) correlates with disease severity and predicts relapse after antithyroid drug (ATD) withdrawal [48]D5. A TRAb level >5 IU/L at diagnosis is associated with a >70% relapse rate after 12-18 months of ATD [61]A1c. Thyroid volume also matters: a larger goiter (>40 mL) is linked to more severe hyperthyroidism and a higher risk of GO [154]B3b. Toxic nodular goiter: Risk is driven by nodule size, number, and degree of autonomy. Large goiters (>80 mL) may cause compressive symptoms (dysphagia, stridor) and require surgical or radioiodine therapy regardless of biochemical severity [108]D5. Thyroiditis (subacute, silent, -induced type 2): Typically self-limited, but severe thyrotoxicosis can occur. Amiodarone-induced thyrotoxicosis (AIT) requires differentiation into type 1 (iodine-induced, high RAI uptake) and type 2 (destructive, low RAI uptake) because differs: type 1 responds to thionamides, type 2 to glucocorticoids [150]D5. Mixed forms are common and require combined therapy.
Special Populations
Pregnancy: Uncontrolled hyperthyroidism increases risks of miscarriage, preterm birth, preeclampsia, and fetal hyperthyroidism [119]A1c[22]A1c. The Endocrine Society and ATA guidelines recommend maintaining FT4 at the upper limit of the normal range or slightly above, with TSH suppressed but detectable [119]A1c[22]A1c. A TSH <0.1 mIU/L in the first trimester is associated with adverse outcomes (RR 1.5-2.0 for preterm birth) [160]A1a. Children: Pediatric Graves disease has a higher relapse rate after ATD (>70% after 2 years) [157]D5. Prolonged ATD (3-5 years) may increase remission rates to 40-50% [157]D5. Definitive therapy (surgery or RAI) is reserved for those who fail ATD or have severe disease [161]B2a. Elderly: Apathetic hyperthyroidism (weight loss, weakness, depression without tachycardia) is common. Atrial fibrillation occurs in 15-25% of elderly patients with overt hyperthyroidism [46]D5. Beta-blockade is essential even in subclinical disease if heart rate is >90 bpm [61]A1c.
Risk Stratification for Graves Orbitopathy
GO severity is graded by the EUGOGO classification: mild (lid retraction <2 mm, soft tissue involvement, proptosis <3 mm above normal, no diplopia), moderate-to-severe (lid retraction ≥2 mm, moderate soft tissue involvement, proptosis ≥3 mm, inconstant or constant diplopia), and sight-threatening (dysthyroid optic neuropathy, corneal ulceration) [23]A1c[49]D5. Disease activity is assessed by the Clinical Activity Score (CAS): a CAS ≥3/7 indicates active disease and predicts response to immunosuppression [23]A1c. Risk factors for severe GO include smoking (OR 3.1), high TRAb, male sex, older age, and prior RAI therapy [49]D5. Selenium supplementation (100-200 µg/day) reduces progression in mild GO in selenium-deficient areas [159]A1a.
Table: Severity Tiers and Management Implications
| Tier | Biochemical | Clinical | Complications | Management Intensity |
|---|---|---|---|---|
| Low (subclinical) | TSH suppressed, FT4/FT3 normal | Asymptomatic or mild | Low CVD risk | Monitor TSH/FT4 every 6-12 months; consider beta-blocker if elderly or heart rate >90 bpm [61]A1c |
| Moderate (overt mild) | FT4 elevated, FT3 normal | Symptomatic (tachycardia, tremor) | Moderate CVD risk | Start ATD (methimazole 10-20 mg/day) or RAI; beta-blocker for symptom control [61]A1c |
| High (overt severe) | FT4 and FT3 markedly elevated | Severe symptoms, atrial fibrillation | High risk of thyroid storm | Urgent beta-blocker (propranolol 40-80 mg every 6 hours), high-dose ATD (methimazole 30-40 mg/day), consider hospitalization [61]A1c |
| Very high (thyroid storm) | Extreme elevations | Altered mental status, fever, tachycardia | Life-threatening | ICU admission, beta-blocker, ATD, steroids, supportive care (see Section 7) [61]A1c |
Pearl: Severity stratification in hyperthyroidism integrates biochemical grade, clinical complications, etiology, and special population risks to guide treatment intensity and surveillance; even subclinical disease carries cardiovascular risk that warrants monitoring and, in selected patients, intervention [149]A1a[61]A1c.
Acute Management and Endocrine Emergencies
- ▸Thyroid storm (BWPS ≥45) demands simultaneous methimazole 30 mg PO, propranolol 60-120 mg PO, and iodine 1 hour after ATD.
- ▸Therapeutic plasma exchange (TPE) reduces T4/T3 by 60-80% and is an effective bridge to thyroidectomy in refractory storm.
- ▸Thyrotoxic periodic paralysis is treated with IV KCl at 10 mmol/h plus propranolol; never use bicarbonate or insulin+glucose.
Severe hyperthyroidism can decompensate into life-threatening crises that demand a time-critical, drug-specific pathway. The three acute presentations, , thyrotoxic (TPP), and thyrotoxic cardiomyopathy, each require immediate action distinct from routine outpatient .
Step 1: Initial Assessment and Severity Classification
Thyroid storm is diagnosed clinically by the Burch-Wartofsky Point Scale (BWPS). A score ≥45 indicates imminent storm; 25-44 is impending storm [48]D5 (5). Immediate ICU admission is mandatory for any patient with a BWPS ≥25 or with organ decompensation (altered mental status, heart failure, hypotension) [30]D5 (5). The 2016 ATA guideline recommends using BWPS and initiating therapy without waiting for confirmatory laboratory results if clinical suspicion is high (strong recommendation, moderate-quality evidence) [83]D5 (5). Thyroid storm has a reported mortality of 10-30%, underscoring the need for rapid recognition [48]D5 (5).
For TPP, severity is graded by the degree of hypokalemia and muscle weakness. Serum potassium is typically <3.0 mmol/L on presentation, with levels dropping as low as 1.5-2.0 mmol/L [110]B2b (2b). Any patient with acute flaccid paralysis, hypokalemia, and tachycardia should be presumed to have TPP until proven otherwise [30]D5 (5).
Step 2: First-Line Intervention for Thyroid Storm
Initiate three simultaneous drug classes within the first hour.
1. Antithyroid drug (ATD), Methimazole (MMI) 20-30 mg PO or per nasogastric tube, then 20 mg every 4-6 hours. Propylthiouracil (PTU) is an alternative (200-400 mg loading, then 200-400 mg every 6-8 hours), but MMI is preferred due to superior efficacy and lower hepatotoxicity; the 2016 ATA guideline recommends MMI as first-line (strong recommendation, high-quality evidence) [83]D5 (5). PTU retains a role in the first trimester of pregnancy or in patients with minor MMI reactions [48]D5 (5).
2. Beta-blockade, Propranolol 60-120 mg PO every 6 hours or 1-2 mg IV every 5-10 minutes, titrated to heart rate <90-100 bpm. Propranolol at high doses also blocks peripheral T4-to-T3 conversion. Esmolol IV infusion (50-200 mcg/kg/min) is an alternative in patients with reactive airway disease [48]D5 (5).
3. Iodine, Saturated solution of potassium iodide (SSKI) 5 drops PO every 6 hours, or Lugol's solution 8 drops every 6 hours, given 1 hour AFTER the first ATD dose. Iodine inhibits new hormone synthesis and release via the Wolff-Chaikoff effect. Iodine must not be given before ATD blockade, as it can paradoxically increase hormone synthesis [88]D5 (5).
In patients with refractory thyrotoxicosis despite maximal medical therapy, iopanoic acid (IOPA) 1 g PO once, then 0.5 g every 6 hours can rapidly restore euthyroidism by inhibiting T4-to-T3 conversion (type 1 deiodinase) and blocking hormone release. In a retrospective series of 13 patients with contraindications or failure of ATD, IOPA reduced FT4 from a median 61 pmol/L to 26 pmol/L within 48 hours, and all patients proceeded to safe [184]C4 (4).
Step 3: Second-Line Interventions, Escalation Triggers
If the patient fails to improve (BWPS unchanged or rising) after 24-48 hours of maximal medical therapy, or if surgery is required urgently:
-
(TPE), performed daily or every other day, removing 1-1.5 plasma volumes per session. TPE rapidly lowers circulating total T4 and T3 by 60-80% after the first exchange. In a case series of 6 patients with severe thyrotoxicosis or storm, TPE achieved a mean FT4 reduction from >77 pmol/L to <25 pmol/L after 3 sessions, serving as an effective bridge to thyroidectomy [174]C4 (4). The 2016 ATA guideline endorses TPE as a temporizing measure when rapid preoperative normalization is needed (conditional recommendation, low-quality evidence) [83]D5 (5).
-
Lithium carbonate bridging, for severe Graves disease when rapid control is needed before RAI. In a retrospective cohort (n=46), lithium (target serum level 0.6-1.0 mmol/L) given from ATD withdrawal until 7 days post-RAI reduced the 6-month treatment failure rate from 41% to 22% compared with standard care (OR 0.40, 95% CI 0.17-0.91; NNT = 5 to prevent persistent hyperthyroidism) [182]B2b (2b).
Step 4: Monitoring and Titration
In thyroid storm, measure FT4, FT3, TSH, serum potassium, and cardiac telemetry every 6-12 hours. Titrate propranolol to keep heart rate <100 bpm but avoid excessive hypotension. Monitor liver enzymes and blood count due to ATD side effects (hepatotoxicity with PTU, agranulocytosis with MMI) [48]D5 (5). In TPP, check serum K+ hourly during intravenous (IV) potassium repletion until weakness resolves, then every 2-4 hours for 24 hours to prevent rebound hyperkalemia.
Step 5: Resolution, Transition, and Disposition
Once the patient is hemodynamically stable, mentation normal, and FT4/FT3 trending downward, transition to a definitive management plan (long-term ATD, RAI, or thyroidectomy). Thyroid storm typically resolves over 5-14 days [48]D5 (5). Discharge criteria include: euthyroid state (or near-euthyroid), heart rate <90 bpm off IV beta-blockers, and no signs of organ failure.
Thyrotoxic Periodic Paralysis (TPP): A Hypokalemic Emergency
TPP is a hyperthyroidism complication seen predominantly in young Asian men (male-to-female ratio 20:1) [110]B2b (2b). Paralysis results from an acute intracellular potassium shift triggered by high thyroid hormone levels, often after a high-carbohydrate meal or exercise. The hallmark is flaccid, areflexic paralysis with serum K+ typically <3.0 mmol/L [109]B2b (2b).
- Potassium repletion: Administer IV potassium chloride (KCl) at 10 mmol/hour until weakness resolves. In a prospective interventional study (n=78), the mean KCl dose needed for full recovery was 63±32 mmol, and peak serum K+ after recovery was 4.0±0.3 mmol/L [109]B2b (2b). Higher infusion rates (≥20 mmol/h) risk rebound hyperkalemia and are not recommended [110]B2b (2b). Do NOT use potassium for TPP outside the acute setting.
- Beta-blockade: Propranolol 40-80 mg PO immediately, then 40-80 mg every 6 hours, both treats hyperthyroidism and prevents recurrence of paralysis. A high-carbohydrate meal challenge (glucose loading) can trigger paralysis, so patients should avoid simple sugars until euthyroid [110]B2b (2b).
- Definitive treatment: Correct the underlying hyperthyroidism with methimazole 20-40 mg PO daily and proceed to RAI or thyroidectomy once euthyroid [30]D5 (5). TPP does not recur once euthyroidism is restored.
Thyrotoxic Cardiomyopathy and [[Atrial Fibrillation]]
Atrial fibrillation (AF) is the most common cardiac complication of hyperthyroidism, occurring in 10-25% of patients [30]D5 (5). The mechanism is direct thyroid hormone-mediated shortening of the atrial refractory period, not reversible by (which has reduced efficacy) [48]D5 (5).
- Management requires beta-blockade (propranolol 40-120 mg PO every 6-8 hours) to slow ventricular response. If a low left ventricular ejection fraction (LVEF <40%) is present, use 2.5-10 mg PO daily or a cardioselective beta-blocker [30]D5 (5).
- Anticoagulation for AF in hyperthyroidism follows criteria, but hyperthyroid patients have an inherently higher thromboembolic risk. The 2016 ATA guideline recommends anticoagulation for patients with AF and one or more additional risk factors (CHADS2 ≥1) until 4-6 weeks after restoration of sinus rhythm (conditional recommendation, low-quality evidence) [83]D5 (5). Direct oral anticoagulants (DOACs) are preferred over unless the patient has valvular AF or is hemodynamically unstable [48]D5 (5).
- Spontaneous conversion to sinus rhythm occurs in the majority within 4-6 weeks of achieving euthyroidism; therefore, electrical cardioversion should be deferred until the patient is euthyroid unless hemodynamic instability mandates urgent intervention [83]D5 (5).
| Drug | Mechanism | Starting Dose | Key Monitoring | Evidence Level |
|---|---|---|---|---|
| Methimazole | Inhibits thyroid peroxidase | 30-40 mg PO once, then 20 mg q4-6h | CBC (agranulocytosis), LFTs | 1b [48]D5 |
| Propylthiouracil | Inhibits TPO + peripheral T4→T3 | 200-400 mg PO load, then 200 mg q6h | LFTs (hepatotoxicity), CBC | 1b [48]D5 |
| Propranolol (non-selective β-blocker) | Blocks β-adrenergic + T4→T3 | 60-120 mg PO q6h or 1-2 mg IV | HR, BP, ECG | 1b [48]D5 |
| Saturated solution of potassium iodide (SSKI) | Wolff-Chaikoff effect | 5 drops PO q6h | Thyroid function, iodine allergy | 4 [88]D5 |
| Iopanoic acid | Type 1 deiodinase inhibitor | 1 g PO, then 0.5 g q6h | FT4, FT3 q12h | 4 [184]C4 |
| KCl (for TPP) | Potassium repletion | 10 mmol/h IV | Serum K+ hourly | 2b [109]B2b |
| Lithium carbonate | Inhibits thyroid hormone release | 300-450 mg PO q8h (target 0.6-1.0 mmol/L) | Lithium level, BUN, Cr | 2b [182]B2b |
What NOT to Do
- Do NOT administer iodine before an ATD in thyroid storm, iodine alone can increase hormone synthesis and worsen the storm [88]D5 (5).
- Do NOT use digoxin for rate control in hyperthyroid AF, it has reduced efficacy due to increased renal clearance and resistance [48]D5 (5).
- Do NOT use bicarbonate or insulin+glucose for TPP potassium shifts, these are ineffective and risk iatrogenic harm; only adequate potassium repletion and beta-blockade are effective [109]B2b (2b).
- Do NOT perform electrical cardioversion for AF unless the patient is hemodynamically unstable or remains in AF after 4-6 weeks of euthyroidism, as spontaneous conversion is common [83]D5 (5).
Treatment Failure Protocol
If thyroid storm does not improve (BWPS unchanged or rising) after 24-48 hours of maximal medical therapy (MMI + propranolol + iodine):
- Add iopanoic acid (if available) [184]C4 (4).
- Initiate therapeutic plasma exchange, daily 1.5-volume exchanges [174]C4 (4).
- Consider urgent thyroidectomy if the patient is a surgical candidate despite elevated FT4/FT3; a recent retrospective cohort (n=275) found no difference in major complications between controlled vs uncontrolled hyperthyroidism at the time of surgery, including recurrent laryngeal nerve injury (3.5% vs 3.8%, p=0.91) and hematoma (1.2% vs 1.5%, p=0.87) [177]B2b (2b).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Urgent thyroidectomy before euthyroid state | ATA 2016, recommends achieving euthyroidism before surgery (strong recommendation, low-quality evidence) [83]D5 | Fazendin 2023, retrospective data show safe outcomes in uncontrolled hyperthyroidism (no increased complications) [177]B2b (2b) | Moderate (guideline recommendation vs new evidence) | Clinicians may consider urgent surgery in selected hemodynamically stable patients after ATD + beta-blockade, without mandatory iodine blockade. |
Pearl: In thyroid storm, initiate all three drug classes (ATD, beta-blockade, iodine) within the first hour; for patients failing medical therapy after 24-48 hours, therapeutic plasma exchange rapidly reduces hormone levels and can safely bridge to thyroidectomy, even if euthyroidism is not achieved [83]D5[174]C4.
Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
- ▸Antithyroid drugs (methimazole first-line) are the initial treatment for Graves disease; definitive therapy (RAI or surgery) is preferred for toxic nodular goiter and for Graves patients who relapse or have contraindications to ATDs.
- ▸Long-term ATD therapy (≥5 years) is safe and effective for patients who prefer to avoid definitive therapy, with remission rates increasing over time.
- ▸RAI is contraindicated in pregnancy and active moderate-to-severe Graves orbitopathy; steroid prophylaxis is required when RAI is used in patients with mild orbitopathy or risk factors.
Selecting among antithyroid drugs (ATDs), radioactive iodine (RAI), and surgery requires balancing efficacy, safety, and patient preference, with the goal of achieving sustained euthyroidism [48]D5[52]D5. The choice hinges on etiology, Graves disease versus toxic nodular goiter, and on patient factors such as age, pregnancy plans, comorbidity, and the presence of Graves orbitopathy (GO) [61]A1c[75]D5. The treat-to-target paradigm demands that therapy be titrated to a defined biochemical endpoint: a normal serum TSH (0.4-4.0 mIU/L) with free T4 and free T3 within reference ranges [52]D5[61]A1c. This section outlines a stepwise approach to long-term , from initial decision-making through monitoring and transition to definitive therapy or sustained medical control.
Step 1: Initial Assessment and Treatment Selection
Classify the patient by etiology and severity before choosing a modality. For Graves disease, the 2016 American Thyroid Association (ATA) guideline recommends ATDs as first-line therapy for most patients, particularly those with mild disease, small goiters, or negative TRAb [61]A1c (strong recommendation, moderate-quality evidence). For toxic nodular goiter (solitary or multinodular), ATDs are not curative; RAI or surgery is preferred because spontaneous remission is rare [83]D5[84]D5. Assess for contraindications: RAI is contraindicated in pregnancy, lactation, and active moderate-to-severe GO [61]A1c[75]D5; surgery is preferred when GO is active or when rapid normalization of thyroid function is needed (e.g., severe cardiac disease) [55]A1a. Beta-blockers (e.g., propranolol 20-40 mg every 6 hours or 25-50 mg daily) should be initiated in all symptomatic patients to control tachycardia, tremor, and anxiety until euthyroidism is achieved [61]A1c[83]D5.
Step 2: First-Line Medical Therapy, Antithyroid Drugs
Methimazole (MMI) is the ATD of choice for non-pregnant adults [61]A1c[84]D5. The starting dose is 10-30 mg once daily, depending on baseline free T4 elevation: 10-15 mg for mild, 20-30 mg for moderate-to-severe hyperthyroidism [61]A1c. Propylthiouracil (PTU) is reserved for the first trimester of pregnancy (due to lower teratogenicity risk), for patients with minor adverse reactions to MMI, and for [61]A1c[119]A1c. PTU is dosed 100-150 mg every 8 hours (300-450 mg/day) [61]A1c. A block-and-replace regimen (fixed high-dose ATD plus ) is not recommended because it increases ATD exposure without improving remission rates [89]A1a (Cochrane review, 26 RCTs, N=3388).
Monitoring during ATD therapy: Check TSH, free T4, and free T3 every 4-6 weeks until euthyroid, then every 3-6 months [61]A1c. The goal is to maintain TSH in the normal range. Once euthyroid, reduce MMI to the lowest effective dose (typically 5-10 mg daily) [61]A1c. Warn patients about agranulocytosis (risk ~0.3%): instruct them to stop the drug and seek immediate medical attention if fever or sore throat develops [61]A1c[84]D5. Baseline and periodic complete blood counts are not routinely recommended unless symptoms arise [61]A1c.
Duration of ATD therapy: The conventional course is 12-18 months [61]A1c[89]A1a. After withdrawal, remission occurs in approximately 40-50% of patients, with higher rates in those who become TRAb-negative and have small goiters [61]A1c[89]A1a. For patients who relapse after a full course, or who prefer to avoid definitive therapy, long-term ATD therapy (≥5 years) is safe and effective [31]D5. The Endocrine Society 2024 review notes that remission rates increase with longer treatment duration, reaching 70-80% after 5-10 years [31]D5.
Step 3: Definitive Therapy, Radioactive Iodine and Surgery
Radioactive iodine (RAI) is a well-established definitive treatment for Graves disease and toxic nodular goiter [40]D5[61]A1c. Administer 131I as a fixed dose of 10-15 mCi (370-555 MBq) or a calculated dose based on thyroid uptake and volume [61]A1c[187]B2a. The goal is to induce hypothyroidism, which is then managed with levothyroxine. RAI is contraindicated in pregnancy, , and active moderate-to-severe GO [61]A1c[75]D5. In patients with mild GO or risk factors (smoking, high TRAb), prophylaxis (0.2-0.5 mg/kg/day for 6-12 weeks) is recommended to prevent progression [61]A1c[75]D5. After RAI, monitor TSH and free T4 every 4-6 weeks for the first 6 months; hypothyroidism typically develops within 3-6 months [61]A1c. Early transient hypothyroidism (TSH >4.2 mIU/L) occurs in ~27% of patients and is associated with a higher likelihood of permanent hypothyroidism [200]B2b (2b).
Surgery (total ) is indicated when RAI is contraindicated, when GO is active, when a large goiter causes compressive symptoms, or when coexistent thyroid cancer is suspected [55]A1a[61]A1c. Subtotal thyroidectomy is associated with higher recurrence rates and is no longer recommended [55]A1a (Cochrane review, 5 RCTs, N=789). Total thyroidectomy achieves immediate cure but carries risks of permanent (1-2%) and recurrent laryngeal nerve injury (1-2%) in high-volume centers [55]A1a. After surgery, start levothyroxine 1.6-1.8 mcg/kg/day and titrate to a normal TSH [61]A1c.
Step 4: Monitoring and Titration After Definitive Therapy
After RAI or surgery, lifelong follow-up is required. For RAI-treated patients, check thyroid function every 4-6 weeks until stable, then annually [61]A1c. For surgically treated patients, start levothyroxine immediately and check TSH 6-8 weeks after initiation, then annually once stable [61]A1c. The target TSH is 0.5-2.5 mIU/L for most adults; in older patients or those with cardiac disease, a slightly higher target (1.0-4.0 mIU/L) may be appropriate [131]D5. Monitor for complications: after RAI, rare risks include radiation thyroiditis and, in long-term follow-up, a possible small increase in cancer mortality (absolute risk ~1-2% excess) [191]D5 (5). After surgery, monitor calcium and PTH for hypoparathyroidism [55]A1a.
Step 5: Transition and Special Populations
Pregnancy: ATDs are the mainstay. Use PTU in the first trimester (due to lower risk of MMI embryopathy: aplasia cutis, ) and switch to MMI in the second trimester [61]A1c[119]A1c[133]D5. The goal is to maintain free T4 at the upper limit of the normal pregnancy-specific range [61]A1c. RAI is absolutely contraindicated during pregnancy [61]A1c. Surgery is reserved for rare cases of ATD intolerance or severe disease [61]A1c.
Graves orbitopathy (GO): For mild GO, any treatment is acceptable, but if RAI is chosen, steroid prophylaxis is mandatory [61]A1c[75]D5. For moderate-to-severe active GO, ATDs or surgery are preferred; RAI should be avoided [75]D5 (2025 JCEM guideline). Selenium supplementation (200 mcg daily) may improve quality of life in mild GO [23]A1c.
Elderly: Older adults with overt hyperthyroidism should be treated due to cardiovascular risk [131]D5. ATDs are first-line, but lower starting doses (MMI 5-10 mg daily) are recommended to avoid overtreatment [131]D5. RAI is effective but may require longer time to achieve euthyroidism [131]D5.
Children: ATDs are first-line; MMI is preferred over PTU due to PTU hepatotoxicity [61]A1c. RAI is an option after age 5-10 years, but concerns about long-term cancer risk persist [61]A1c. Surgery is reserved for large goiters or ATD failure [61]A1c.
Drug / Modality Comparison Table
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Methimazole (MMI) | First-line for Graves (non-pregnant) | 10-30 mg once daily, then 5-10 mg maintenance | ATA 2016 [61]A1c; Cochrane 2010 [89]A1a | Remission 40-50% after 12-18 mo | 1a |
| Propylthiouracil (PTU) | First trimester pregnancy; MMI intolerance | 100-150 mg every 8 hours | ATA 2016 [61]A1c; Endocrine Society 2012 [119]A1c | Less teratogenic than MMI | 1c |
| Radioactive iodine (131I) | Definitive for Graves and toxic nodular goiter | 10-15 mCi fixed dose | ATA 2016 [61]A1c; Cochrane 2016 [138]A1a | Hypothyroidism in >80% at 1 year | 1a |
| Total thyroidectomy | Definitive when RAI contraindicated or GO active | , | Cochrane 2015 [55]A1a | Cure rate >95%; permanent hypoparathyroidism 1-2% | 1a |
| Beta-blockers | Symptom control | Propranolol 20-40 mg q6h or atenolol 25-50 mg daily | ATA 2016 [61]A1c | Rapid symptom relief | 5 |
Dosing Table
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Methimazole | 10-30 mg PO once daily | 5-10 mg daily (maintenance) | None | Caution in severe hepatic impairment | CBC if fever/sore throat; TSH, FT4 q4-6wk |
| Propylthiouracil | 100-150 mg PO q8h | 300-450 mg/day | None | Avoid in active liver disease; monitor LFTs | CBC, LFTs; TSH, FT4 q4-6wk |
| Levothyroxine (post-definitive) | 1.6-1.8 mcg/kg/day | TSH 0.5-2.5 mIU/L | None | None | TSH 6-8 wk after initiation, then annually |
| Propranolol | 20-40 mg PO q6h | 80-160 mg/day | Reduce dose in renal impairment | Caution in hepatic impairment | Heart rate, blood pressure |
Treatment Failure Protocol
ATD failure is defined as persistent hyperthyroidism after 6-12 months of adequate dosing, or relapse after withdrawal. In such cases, offer definitive therapy (RAI or surgery) [61]A1c. For patients who decline definitive therapy, long-term ATD (≥5 years) is an option [31]D5. RAI failure (persistent hyperthyroidism at 6 months) occurs in 10-20% of patients; repeat RAI or proceed to surgery [61]A1c. Surgical failure (persistent hyperthyroidism) is rare after total thyroidectomy; check for remnant tissue and consider RAI [55]A1a.
What NOT to Do
- Do NOT use ATDs as first-line for toxic nodular goiter, remission is unlikely, and definitive therapy is preferred [83]D5[84]D5.
- Do NOT use block-and-replace ATD regimens, they increase drug exposure without improving remission [89]A1a.
- Do NOT administer RAI during pregnancy or breastfeeding, it causes fetal thyroid ablation [61]A1c.
- Do NOT use PTU in children or as first-line in non-pregnant adults, hepatotoxicity risk [61]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Optimal ATD duration | ATA 2016, 12-18 months, then reassess [61]A1c | Endocrine Society 2024, consider ≥5 years for higher remission [31]D5 | Moderate (different thresholds for long-term therapy) | Clinicians may extend ATD beyond 18 months in motivated patients; shared decision-making is key. |
| RAI and cancer risk | ATA 2016, RAI is safe with no significant cancer excess [61]A1c | Kitahara et al. 2019, reanalysis of CTTFUS suggests small excess mortality from solid cancers (RR 1.14, 95% CI 1.01-1.29) [191]D5 | Moderate (newer data challenge prior safety assumption) | Discuss the small absolute risk with patients; RAI remains appropriate for most, but caution in young adults. |
| Surgery vs RAI for GO | EUGOGO 2021, ATDs or surgery preferred for moderate-to-severe active GO; RAI avoided [23]A1c | ATA 2016, RAI with steroid prophylaxis acceptable even in mild GO [61]A1c | Strong (incompatible recommendations for active GO) | In active moderate-to-severe GO, choose surgery or ATDs; for mild GO, RAI with prophylaxis is acceptable. |
Management Algorithm
Figure 1: Long-term management algorithm for hyperthyroidism (adapted from ATA 2016 [61]A1c and EUGOGO 2021 [23]A1c).
Pearl: For Graves disease, start with methimazole 10-30 mg daily and titrate to normal TSH; after 12-18 months, reassess for remission; if relapse occurs, offer definitive therapy with RAI or surgery, but in active Graves orbitopathy, avoid RAI and choose ATDs or surgery instead [61]A1c[75]D5.
Multiglandular Syndromes, Genetic Context and Co-Axis Effects
- ▸Hyperthyroidism can be a component of monogenic syndromes (McCune-Albright, Carney complex, MCT8 deficiency, resistance to thyroid hormone, TSHR mutations) that require syndromic screening.
- ▸Autoimmune hyperthyroidism clusters with other autoimmune endocrinopathies in polyglandular syndromes (APS-2, monogenic autoimmune syndromes) and can be triggered by immune-modulating therapies (alemtuzumab, SARS-CoV-2 vaccination).
- ▸Hyperthyroidism perturbs multiple endocrine axes (liver, bone, coagulation, reproduction, cardiovascular, adrenal, neurological) necessitating cross-axis surveillance for complications.
Endocrine lesions rarely sit in isolation: hyperthyroidism may be the presenting feature of an inherited tumor syndrome or a monogenic disorder that mandates syndromic screening and cross-axis surveillance.
Monogenic Syndromes Presenting with Hyperthyroidism
Several rare monogenic disorders feature hyperthyroidism as a core or occasional manifestation. McCune-Albright syndrome (MAS) results from postzygotic activating mutations in GNAS, leading to constitutive Gsα activity and autonomous hyperfunction in multiple endocrine glands. Hyperthyroidism in MAS is typically due to toxic nodular goiter or diffuse hyperplasia, often presenting in childhood alongside fibrous dysplasia, café-au-lait spots, and [116]C4. Carney complex (CNC), caused by PRKAR1A mutations, includes spotty skin pigmentation, cardiac myxomas, and endocrine overactivity; thyroid follicular adenomas are common, and Graves' disease has been reported in association [114]C4. Monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome) is an X-linked disorder causing severe intellectual disability and peripheral thyrotoxicosis due to impaired T3 transport into neurons. Affected males have elevated serum T3, suppressed TSH, and progressive weight loss, tachycardia, and muscle wasting [188]C4[206]C4. Resistance to thyroid hormone (RTH), typically due to THRB mutations, presents with elevated free T4 and T3 with inappropriately normal or high TSH; some patients exhibit thyrotoxic [204]C4. Hereditary nonautoimmune hyperthyroidism is caused by germline activating mutations in the TSHR gene, leading to lifelong hyperthyroidism with goiter and suppressed TSH [207]C4. TSH-secreting pituitary adenomas (TSHomas) are a rare cause of central hyperthyroidism; diagnosis is often delayed due to misinterpretation of elevated TSH with high thyroid hormones [113]C4.
| Syndrome | Gene | Mechanism | Key Features |
|---|---|---|---|
| McCune-Albright syndrome | GNAS (postzygotic) | Constitutive Gsα activity | Fibrous dysplasia, café-au-lait spots, precocious puberty, hyperthyroidism [116]C4 |
| Carney complex | PRKAR1A | Protein kinase A dysregulation | Spotty skin pigmentation, cardiac myxomas, thyroid adenomas, Graves' disease [114]C4 |
| MCT8 deficiency | SLC16A2 | Impaired T3 transport into neurons | Severe intellectual disability, peripheral thyrotoxicosis, muscle wasting [188]C4[206]C4 |
| Resistance to thyroid hormone | THRB | Reduced T3 receptor affinity | Elevated T4/T3 with inappropriately normal TSH, periodic paralysis [204]C4 |
| Hereditary nonautoimmune hyperthyroidism | TSHR | Constitutively active TSHR | Lifelong hyperthyroidism, goiter, suppressed TSH [207]C4 |
| TSH-secreting pituitary adenoma | , | Autonomous TSH secretion | Central hyperthyroidism, delayed diagnosis [113]C4 |
Autoimmune Polyglandular Syndromes
Graves' disease frequently clusters with other autoimmune endocrinopathies. In autoimmune polyglandular syndrome type 2 (APS-2), Graves' disease or Hashimoto's thyroiditis coexists with type 1 diabetes and primary adrenal insufficiency (Schmidt syndrome). Monogenic autoimmune syndromes due to mutations in AIRE (APS-1), FOXP3 (IPEX), or STAT1/STAT3 cause early-onset, severe autoimmunity including hyperthyroidism [137]D5. In children with hyperthyroidism, 3% have associated autoimmune or genetic diseases, most commonly type 1 diabetes and [209]B2c. Alemtuzumab therapy for multiple sclerosis induces Graves' disease in 30-40% of patients, with TRAb appearing years before clinical dysfunction [210]B3b. SARS-CoV-2 mRNA vaccination has been linked to new-onset or relapsed Graves' disease, typically within weeks [172]C4. Mendelian randomization suggests a bidirectional causal relationship between severity and thyroid dysfunction [155]B2c; long-term thyroid complications post-COVID include Graves' disease [183]B2a.
Cross-Axis Effects of Hyperthyroidism
Hyperthyroidism exerts profound effects on other endocrine and metabolic systems.
Thyroid-Liver Axis: Hyperthyroidism increases hepatic gluconeogenesis and glycogenolysis, exacerbating insulin resistance. It also accelerates cholesterol metabolism, lowering LDL but increasing free fatty acids. Overt hyperthyroidism can cause liver injury, including cholestasis and rarely liver failure, especially when combined with other stressors [142]C4[193]D5.
Hemostatic Axis: Hyperthyroidism shifts hemostasis toward a prothrombotic state, with increased levels of fibrinogen, factor VIII, and von Willebrand factor, and reduced fibrinolysis. This may contribute to increased risk of venous thromboembolism [212]D5.
Bone and Mineral Metabolism: Excess thyroid hormone increases bone turnover, leading to reduced bone mineral density and increased fracture risk, particularly in postmenopausal women. Hyperthyroidism can also cause due to increased bone resorption and decreased renal calcium excretion.
Reproductive Axis: Hyperthyroidism disrupts the hypothalamic-pituitary-gonadal axis, causing menstrual irregularities, reduced fertility, and increased risk of miscarriage. In males, hyperthyroidism is associated with reduced sperm quality and infertility [163]A1a.
Cardiovascular Axis: Thyroid hormone directly increases heart rate and contractility, and lowers systemic vascular resistance. Chronic hyperthyroidism leads to , , and increased risk of heart failure. T3 acutely improves endothelial function [165]A1b, but chronic excess is detrimental.
Adrenal Axis: Hyperthyroidism accelerates cortisol clearance, potentially unmasking adrenal insufficiency. Conversely, rapid reduction of glucocorticoids after Cushing's surgery can trigger TSH secretion and hyperthyroidism [203]C4.
Neurological and Psychiatric Effects: Hyperthyroidism is associated with increased risk of depression and anxiety [202]B2b. Anti-GAD65 can present with hyperthyroidism [180]C4.
Genetic Susceptibility and Syndromic Screening
The heritability of thyroid function set points is estimated at 40-60% [216]D5. In patients with hyperthyroidism, especially those with atypical features (young age, family history, associated tumors, or skin lesions), genetic testing should be considered. Screening for syndromic features includes: spotty skin pigmentation (Carney complex), café-au-lait spots and fibrous dysplasia (McCune-Albright), intellectual disability and hypotonia (MCT8 deficiency), and periodic paralysis (RTH). For autoimmune hyperthyroidism, screening for other autoimmune diseases (type 1 diabetes, adrenal insufficiency, ) is warranted, particularly in children.
Pearl: Hyperthyroidism may be the sentinel event for an underlying monogenic syndrome (McCune-Albright, Carney complex, MCT8 deficiency) or autoimmune polyglandular syndrome; syndromic screening and cross-axis surveillance are essential to prevent missed diagnoses and manage multisystem complications.
Complications and Long-term Sequelae
- ▸Cardiovascular complications (AF, HF, stroke, mortality) are the most common and serious long-term sequelae, with risk persisting even after euthyroidism is restored.
- ▸Skeletal complications, particularly hip fracture in postmenopausal women, are increased 1.5-fold and require DXA screening and osteoporosis management.
- ▸Treatment choice influences long-term outcomes: surgery is associated with the lowest all-cause mortality, while radioiodine carries higher cardiovascular mortality and risk of worsening Graves orbitopathy.
Even after biochemical control is achieved, the legacy of hyperthyroidism persists in damaged target organs, demanding lifelong surveillance for cardiovascular, skeletal, and neuropsychiatric sequelae. Chronic exposure to excess thyroid hormone, whether overt or subclinical, accelerates cardiovascular disease, bone loss, and cognitive decline, while treatment itself introduces new risks such as permanent hypothyroidism and worsening Graves orbitopathy.
Cardiovascular Complications
(AF) is the most common cardiovascular complication, occurring in 10-20% of patients with overt hyperthyroidism [125]B2b. The risk remains elevated even after euthyroidism is restored, with a hazard ratio of 1.42 (95% CI 1.15-1.76) for incident AF in previously hyperthyroid individuals compared with euthyroid controls [91]B2b. Subclinical hyperthyroidism (TSH <0.45 mIU/L) also confers a 1.5- to 2-fold increased risk of AF [77]D5[149]A1a. Heart failure, predominantly high-output failure, develops in up to 6% of patients with overt disease and is associated with a 2.6-fold increase in mortality [46]D5[77]D5. Stroke risk rises in parallel with AF, with an adjusted HR of 1.37 (95% CI 1.05-1.79) [125]B2b. All-cause mortality is increased by 20-40% in overt hyperthyroidism (pooled RR 1.21, 95% CI 1.07-1.36) and by 19% in subclinical hyperthyroidism (RR 1.19, 95% CI 1.10-1.29) [186]B2a[149]A1a[218]A1a. Cardiovascular mortality specifically is elevated, with an HR of 1.52 (95% CI 1.28-1.80) in a large Danish cohort [125]B2b. Choice of therapy may modulate risk: a linked-record cohort found that radioiodine-treated patients had higher cardiovascular mortality than those treated with antithyroid drugs (HR 1.36, 95% CI 1.02-1.82) [29]B3b. A network meta-analysis confirmed that surgery is associated with the lowest all-cause mortality (HR 0.67 vs. antithyroid drugs), while radioiodine carries the highest cardiovascular mortality (HR 1.24) [217]A1a.
Skeletal Complications
Hyperthyroidism accelerates bone turnover, shortening the remodeling cycle and leading to net bone loss, particularly at cortical sites [224]D5. The risk of osteoporosis and fracture is most pronounced in postmenopausal women. In a Swedish population-based study of 2134 patients with Graves disease, the fracture incidence was 1.5-fold higher than in matched controls (HR 1.50, 95% CI 1.20-1.87) [222]B3b. The risk was highest for hip fractures (HR 1.74, 95% CI 1.18-2.56). Even subclinical hyperthyroidism is associated with reduced bone mineral density at the femoral neck and lumbar spine [35]D5. TSH itself may have an independent anti-osteoclastic effect; low TSH levels in hyperthyroidism contribute to bone loss beyond the effect of elevated thyroid hormones [35]D5. Restoration of euthyroidism improves bone density but does not fully normalize fracture risk, especially in older adults [222]B3b.
Neuropsychiatric and Cognitive Sequelae
Anxiety, irritability, and emotional lability are hallmark neuropsychiatric manifestations of hyperthyroidism. Long-term follow-up studies reveal a persistent increase in the risk of suicide. In a Swedish cohort of 43,633 patients treated for hyperthyroidism, the standardized mortality ratio for suicide was 1.35 (95% CI 1.05-1.72) [124]B2b. Cognitive impairment, including deficits in attention and executive function, can persist even after biochemical normalization [48]D5. The mechanism involves direct thyroid hormone effects on cerebral metabolism and neurotransmitter systems.
Metabolic and Systemic Effects
Chronic hyperthyroidism induces a catabolic state with weight loss, muscle wasting, and proximal myopathy. Thyroid hormone excess increases basal metabolic rate by 20-50% [48]D5. Hepatic steatosis may be paradoxically reduced in hyperthyroidism, but the relationship is complex; a large NHANES analysis found that subclinical hyperthyroidism was associated with a lower prevalence of metabolic dysfunction-associated fatty liver disease (OR 0.72, 95% CI 0.56-0.93) but no difference in mortality [7]B2b. Renal function can be affected: hyperthyroidism increases renal blood flow and glomerular filtration rate, but long-standing disease may contribute to chronic kidney disease progression [219]B3b.
Reproductive and Pregnancy Complications
Uncontrolled hyperthyroidism during pregnancy increases the risk of miscarriage, preterm delivery, preeclampsia, and low birth weight [26]B2b[51]D5. In a prospective multicenter cohort, women with first-trimester Graves disease had a 2.5-fold higher risk of preterm birth compared with euthyroid controls (OR 2.52, 95% CI 1.38-4.60) [26]B2b. Gestational transient thyrotoxicosis, while less severe, also carries increased risks of pregnancy-induced and [26]B2b. Maternal thyroid-stimulating hormone receptor antibodies (TRAbs) cross the placenta and can cause fetal or neonatal hyperthyroidism [51]D5.
Treatment-Related Long-term Sequelae
Definitive therapy with radioactive iodine (RAI) or surgery inevitably leads to permanent hypothyroidism, requiring lifelong replacement. RAI is associated with a 15-20% risk of worsening Graves orbitopathy, particularly in smokers and those with pre-existing eye disease [221]D5. Prophylactic glucocorticoids ( 0.3-0.5 mg/kg/day for 3 months) reduce this risk by 60-70% [221]D5. Surgery carries risks of (transient in 10-20%, permanent in 1-3%) and recurrent laryngeal nerve injury (1-2%) [55]A1a. Antithyroid drugs can cause agranulocytosis (0.3-0.5%) and hepatotoxicity, but these are acute rather than long-term sequelae [34]D5. Long-term cancer mortality does not appear to be increased by any treatment modality, though data are limited [217]A1a.
Table: Major Complications of Hyperthyroidism
| Complication | Frequency | Prevention | |
|---|---|---|---|
| Atrial fibrillation | 10-20% in overt hyperthyroidism [125]B2b | Achieve and maintain euthyroidism | Rate control (beta-blockers), anticoagulation (CHA₂DS₂-VASc-guided) after euthyroidism |
| Heart failure | 6% in overt disease [46]D5 | Early treatment of hyperthyroidism | Diuretics, beta-blockers, ACE inhibitors; treat underlying thyrotoxicosis |
| Osteoporosis/fracture | 1.5-fold increased fracture risk [222]B3b | Screen with DXA in postmenopausal women; ensure adequate calcium/vitamin D | Bisphosphonates if osteoporosis; treat hyperthyroidism |
| Suicide | SMR 1.35 [124]B2b | Monitor mental health; refer for psychiatric support | Antidepressants, psychotherapy; ensure euthyroidism |
| Graves orbitopathy worsening after RAI | 15-20% [221]D5 | Avoid RAI in active moderate-to-severe GO; give prophylactic steroids | Glucocorticoids, selenium; consider surgery |
| Pregnancy complications | Preterm birth OR 2.52 [26]B2b | Preconception counseling; control hyperthyroidism before pregnancy | Antithyroid drugs (propylthiouracil in first trimester, methimazole thereafter) |
| Permanent hypothyroidism after RAI/surgery | 100% after total ; >80% after RAI at 1 year [40]D5 | Patient education; levothyroxine initiation | Levothyroxine replacement with TSH target 0.5-2.5 mIU/L |
Pearl: Cardiovascular and skeletal risks persist long after biochemical normalization, so all patients with a history of hyperthyroidism, even subclinical, should undergo periodic assessment of heart rate, rhythm, and bone density, with a low threshold for intervention [77]D5[222]B3b.
Prognosis, Natural History, Special Populations and Prevention
- ▸Untreated overt hyperthyroidism increases all-cause mortality risk by 36% (RR 1.36, 95% CI 1.20-1.55), largely from cardiovascular causes [186].
- ▸Pregnancy outcomes improve dramatically with ATD control: NNT of 8 to prevent one preterm birth in well-controlled vs poorly controlled Graves disease [195].
- ▸Preconception counseling for women with Graves disease should include delay of pregnancy for at least 6 months after RAI and stabilization on the lowest effective ATD dose [119, 229].
Natural History of Untreated and Treated Hyperthyroidism
Without treatment, overt hyperthyroidism follows a progressive course. In Graves disease, spontaneous remission occurs in fewer than 20% of patients after 12-18 months, and even in those cases, the likelihood of long-term euthyroidism without relapse is low [48]D5. Untreated thyrotoxicosis accelerates cardiovascular mortality: meta-analysis of cohort studies demonstrates a pooled relative risk of 1.36 (95% CI 1.20-1.55) for all-cause mortality, driven largely by , thromboembolic stroke, and heart failure [186]B2a. The absolute risk increase translates to an NNT to prevent one death of approximately 22 over 10 years if hyperthyroidism is effectively treated (NNT calculable from population-attributable fractions in the meta-analysis). For subclinical hyperthyroidism (endogenous, TSH persistently <0.40 mIU/L), the risk of cardiovascular events rises modestly but significantly (RR 1.19, 95% CI 1.10-1.28) and all-cause mortality increases proportionally with the degree of TSH suppression [149]A1a.
With appropriate therapy, prognosis is excellent. Antithyroid drug (ATD) therapy for 12-18 months achieves remission in 40-60% of Graves patients, though relapse rates remain at 50-60% within two years of drug withdrawal [34]D5[48]D5. Definitive therapy (radioactive iodine [RAI] or ) eliminates biochemical hyperthyroidism in over 95% of patients, but RAI is followed by permanent hypothyroidism in 70-85% within the first year, requiring lifelong replacement [83]D5. The choice of primary therapy does not significantly alter all-cause mortality when euthyroidism is restored, though RAI may be associated with a small increase in cardiovascular death in the first year compared with surgery or ATDs (HR 1.21, 95% CI 1.01-1.46; NNH = 167) [29]B3b.
Special Populations
Pregnancy
Pregnancy alters both the natural history and of hyperthyroidism. The most common cause of gestational thyrotoxicosis is gestational transient thyrotoxicosis (GTT), mediated by high hCG levels, which resolves spontaneously by the second trimester and rarely requires antithyroid therapy [136]D5[26]B2b. In contrast, Graves disease persists and, if poorly controlled, increases risks of preterm birth (OR 1.9, 95% CI 1.3-2.7), preeclampsia (OR 2.2, 95% CI 1.5-3.1), and low birthweight (OR 2.3, 95% CI 1.6-3.3) [64]B2a[189]B2a[126]A1a. Adequate control of maternal hyperthyroidism reduces these risks; the NNT to prevent one preterm birth is approximately 8 (based on absolute risk reduction from 25% to 12% in well-controlled vs poorly controlled Graves disease [195]A1a).
Fetal and neonatal risks include central hypothyroidism from transplacental passage of ATDs (especially methimazole, which carries a 2-4% risk of aplasia cutis and rare embryopathy) and, conversely, fetal/neonatal hyperthyroidism from transplacental stimulatory TSH-receptor antibodies (TRAb) when maternal disease is active even after thyroidectomy or RAI [32]D5[133]D5[127]D5. For women who require ATD in pregnancy, propylthiouracil (PTU) is recommended in the first trimester (to minimize methimazole embryopathy), with a switch to methimazole after 16 weeks (to avoid PTU hepatotoxicity) [22]A1c[136]D5[119]A1c. The Endocrine Society and ATA guidelines emphasize preconception counseling: women should delay pregnancy for at least 6 months after RAI (to ensure stable thyroid function) and be euthyroid on the lowest effective ATD dose before conception [119]A1c[229]B2b.
Pediatric Hyperthyroidism
Juvenile Graves disease accounts for most childhood hyperthyroidism. Treatment follows a different calculus because of the long exposure to therapy and the teratogenicity of RAI in future pregnancies. ATDs (methimazole 0.3-0.5 mg/kg/day) remain first-line for 1-2 years, but remission rates are lower than in adults, only 25-30% after 2 years [161]B2a[48]D5. Definitive therapy (total thyroidectomy or RAI) is reserved for relapse, nonadherence, or adverse ATD effects. RAI is considered safe in children over 5 years at doses that achieve hypothyroidism (mean activity 150-200 µCi/g), though studies show a modest increase in benign thyroid nodules later in life but no clear rise in thyroid cancer [161]B2a[32]D5. Surgery (total thyroidectomy) offers cure rates over 95% with a <2% permanent risk in high-volume centers [161]B2a. The choice between RAI and surgery remains controversial; a 2025 meta-analysis found no significant difference in recurrence (OR 1.12, 95% CI 0.68-1.84) but lower overall complication rates with RAI [161]B2a.
Elderly Patients
Older adults (age >65 years) are more vulnerable to the cardiovascular consequences of hyperthyroidism. Overt hyperthyroidism increases the risk of atrial fibrillation by 3- to 5-fold, and in elderly patients, TSH suppression to <0.10 mIU/L is associated with a HR of 1.8 for stroke independent of conventional risk factors [186]B2a[149]A1a. Subclinical hyperthyroidism in the elderly is not benign: a meta-analysis of individual-participant data showed an increased risk of (HR 1.38, 95% CI 1.08-1.76) and functional decline measured by Barthel Index [228]B2b. Treatment decisions in older patients must balance the higher risk of ATD-related agranulocytosis (age >65 is an independent risk factor; incidence ~1 in 200) against the cardiovascular benefits [45]D5. For subclinical hyperthyroidism with TSH persistently <0.10 mIU/L, guidelines recommend treatment to prevent adverse outcomes, especially in those with cardiac risk factors or osteoporosis [149]A1a[228]B2b.
Patients with Chronic Kidney Disease (CKD)
CKD alters thyroid hormone metabolism and increases the prevalence of hyperthyroidism. A systematic review of dialysis patients reported a pooled prevalence of overt hyperthyroidism of 1.8% (95% CI 0.9-3.0%) and subclinical hyperthyroidism of 6.5% (95% CI 4.1-9.5%) [198]B2a. Hyperthyroidism in CKD is associated with faster progression to end-stage renal disease (adjusted HR 1.31, 95% CI 1.12-1.52) and higher all-cause mortality [219]B3b. Treatment with ATDs or definitive therapy is effective, but drug doses must be adjusted: methimazole clearance is reduced in renal impairment, and PTU may accumulate [219]B3b.
Prevention and Screening
Primary prevention of autoimmune hyperthyroidism remains elusive, but strategies mitigate risks. In populations with adequate iodine intake, universal salt iodization reduces the incidence of toxic nodular goiter but does not prevent Graves disease [88]D5. For women of reproductive age, achieving and maintaining euthyroidism before pregnancy is the single most effective intervention; a population-based cohort showed that preconception ATD treatment with stable TSH <2.5 mIU/L was associated with a 60% reduction in adverse pregnancy outcomes compared with untreated hyperthyroidism (aRR 0.4, 95% CI 0.3-0.6) [229]B2b.
Screening for thyroid dysfunction in pregnancy is controversial. The ATA 2026 guidelines recommend targeted screening based on risk factors (age >30, BMI >40, family history of thyroid disease, personal history of autoimmune disease, prior preterm birth, infertility, and symptoms of thyroid dysfunction) because universal screening has not shown clear benefit in reducing adverse outcomes in randomized trials [22]A1c[139]A1a. The Cochrane review of screening found insufficient evidence to support universal screening (very low-quality evidence), though high-risk identification improves detection and treatment [139]A1a. In children, neonatal screening for is standard, but screening for hyperthyroidism is not performed because its incidence (<1:50,000) is lower and clinical presentation is usually evident within the first weeks of life [32]D5.
Vitamin D supplementation has been investigated as a disease-modifying intervention in Graves disease. The DAGMAR trial (n=236) randomized patients with newly diagnosed Graves disease to vitamin D 70 mcg (2800 IU) daily or placebo for up to 36 months. Remission rates at 24 months were 51% in the vitamin D group vs 49% in placebo (aRR 1.04, 95% CI 0.85-1.27), showing no benefit for achieving sustained remission [121]A1b. Therefore, vitamin D supplementation is not recommended as a treatment to alter the natural history of Graves disease.
Pearl: Overt hyperthyroidism, if untreated, doubles cardiovascular mortality and substantially increases pregnancy complications, but effective treatment restores a near-normal prognosis; preconception euthyroidism and careful risk-stratified screening in pregnancy remain the cornerstones of prevention [186]B2a[229]B2b[22]A1c.
| Population | Key Risk | Absolute Risk (Untreated vs Treated) | NNT/NNH | Guideline Recommendation |
|---|---|---|---|---|
| Pregnancy (Graves) | Preterm birth, preeclampsia, LBW | Preterm: 25% vs 12% [195]A1a | NNT 8 for preterm birth [195]A1a | First-trimester PTU, switch to MMI after 16 wk; target TSH 0.1-2.5 mIU/L [22]A1c |
| Pediatric (Graves) | Relapse after ATD, teratogenicity of RAI | Remission at 2 yr: 25-30% [161]B2a | NNH for surgery complications ~2% permanent hypoparathyroidism | ATD first-line; definitive Rx for relapse >5 yr old [161]B2a[48]D5 |
| Elderly (>65 yr) | Atrial fibrillation, stroke, fracture | AF risk: HR ~3.0 for overt; hip fracture HR 1.38 for subclinical [186]B2a[228]B2b | NNH for ATD agranulocytosis ~1/200 in elderly [45]D5 | Treat subclinical if TSH <0.10 mIU/L + cardiac/osteoporosis risk [149]A1a |
| CKD/dialysis | ESRD progression, mortality | Overt hyperthyroidism prevalence 1.8% [198]B2a | , | Adjust ATD doses; consider definitive therapy [219]B3b |
References
- [1]
Yeap BB, Alfonso H, Chubb SA et al.. “Higher free thyroxine levels predict increased incidence of dementia in older men: the Health in Men Study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22977271 ↗
L2RCTCited in: Definition, Classification and Axis Nomenclature - [2]
Aubert CE, Floriani C, Bauer DC et al.. “Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28482002 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature - [3]
Dong AC, Stagnaro-Green A. “Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy: A Systematic Review and Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 30444186 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature - [4]
Khan SR, Bano A, Wakkee M et al.. “The association of autoimmune thyroid disease (AITD) with psoriatic disease: a prospective cohort study, systematic review and meta-analysis.” European journal of endocrinology (2017). PMID: 28747386 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature - [5]
Andersen SL, Andersen S, Vestergaard P et al.. “Maternal Thyroid Function in Early Pregnancy and Child Neurodevelopmental Disorders: A Danish Nationwide Case-Cohort Study.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 29584590 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [6]
Hegedüs L, Bonnema SJ. “Approach to management of the patient with primary or secondary intrathoracic goiter.” The Journal of clinical endocrinology and metabolism (2010). PMID: 21131536 ↗
L5CASE_REPORTCited in: Definition, Classification and Axis Nomenclature - [7]
Chen YL, Tian S, Wu J et al.. “Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637992 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [8]
Zhao W, Kang Q, Qian F et al.. “Convolutional Neural Network-Based Computer-Assisted Diagnosis of Hashimoto's Thyroiditis on Ultrasound.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34907442 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [9]
Kizilgul M, Yigit T, Ata N et al.. “Machine Learning Prediction of Pancreatitis Risk With Antithyroid Drugs: A Nationwide Retrospective Observational Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39324654 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature - [10]
Polkampally S, Halagur AS, Green A et al.. “Incidence of Pediatric Graves' Disease in the United States: An Epidemiological Analysis of 2007-2022 Outpatient Insurance Claims.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40982291 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature - [11]
Andersen SL, Olsen J. “Early Pregnancy Thyroid Function Test Abnormalities in Biobank Sera from Women Clinically Diagnosed with Thyroid Dysfunction Before or After Pregnancy.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 27841706 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [12]
Folkestad L, Brandt F, Lillevang-Johansen M et al.. “Graves' Disease and Toxic Nodular Goiter, Aggravated by Duration of Hyperthyroidism, Are Associated with Alzheimer's and Vascular Dementia: A Registry-Based Long-Term Follow-Up of Two Large Cohorts.” Thyroid : official journal of the American Thyroid Association (2020). PMID: 31984866 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature - [13]
Buurman H, Saeger W. “Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.” European journal of endocrinology (2006). PMID: 16645024 ↗
L4OTHERCited in: Definition, Classification and Axis Nomenclature - [14]
Cooper DS, Biondi B. “Subclinical thyroid disease.” Lancet (London, England) (2012). PMID: 22273398 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [15]
Harding KB, Peña-Rosas JP, Webster AC et al.. “Iodine supplementation for women during the preconception, pregnancy and postpartum period.” The Cochrane database of systematic reviews (2017). PMID: 28260263 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [16]
Fan T, Luo X, Li X et al.. “The Association between Depression, Anxiety, and Thyroid Disease: A UK Biobank Prospective Cohort Study.” Depression and anxiety (2024). PMID: 40226662 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [17]
Miller S, Jiang R, Schipper M et al.. “Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.” The Lancet. Oncology (2024). PMID: 39551068 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [18]
Kim M, Lee J, Hwang YB et al.. “Graves' orbitopathy development in thyroid cancer patients: a 16-year nationwide cohort study in South Korea.” Eye (London, England) (2024). PMID: 38942911 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [19]
Wang X, Li T, Li Y et al.. “Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study.” Journal of translational medicine (2024). PMID: 38553734 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [20]
Kumar R, LeMahieu AM, Stan MN et al.. “The Association Between Thyroid Stimulating Hormone and Depression: A Historical Cohort Study.” Mayo Clinic proceedings (2023). PMID: 37419569 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [21]
Yamichannaiah C, Memon SS, Sarathi V et al.. “Genotype-Phenotype Correlation in Germline TSH Receptor Activating Mutation Associated Hyperthyroidism: A Systematic Review.” Clinical endocrinology (2025). PMID: 40470728 ↗
L4SR_OBSCited in: Definition, Classification and Axis Nomenclature - [22]
Korevaar TIM, Leung AM, Alexander EK et al.. “American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42219800 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [23]
Bartalena L, Kahaly GJ, Baldeschi L et al.. “The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.” European journal of endocrinology (2021). PMID: 34297684 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [24]
Huynh CN, Pearce JV, Kang L et al.. “Weight Gain After Thyroidectomy: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33106852 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [25]
Lishinsky-Fischer N, Pollack R, Gur Z. “Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 41954033 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [26]
Xu Y, Li C, Wang W et al.. “Gestational and Postpartum Complications in Patients with First Trimester Thyrotoxicosis: A Prospective Multicenter Cohort Study from Northeast China.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37051708 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [27]
Søgaard M, Farkas DK, Ehrenstein V et al.. “Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study.” European journal of endocrinology (2016). PMID: 26863886 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [28]
Besançon A, Beltrand J, Le Gac I et al.. “Management of neonates born to women with Graves' disease: a cohort study.” European journal of endocrinology (2014). PMID: 24670885 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [29]
Okosieme OE, Taylor PN, Evans C et al.. “Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.” The lancet. Diabetes & endocrinology (2019). PMID: 30827829 ↗
L3COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [30]
Kostopoulos G, Effraimidis G. “Approach to the patient with severe hyperthyroidism-related complications.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41823424 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [31]
Azizi F, Mehran L, Abdi H et al.. “Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39018185 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [32]
Léger J, Delcour C, Carel JC. “Fetal and Neonatal Thyroid Dysfunction.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34636892 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [33]
Laurberg P, Bournaud C, Karmisholt J et al.. “Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy.” European journal of endocrinology (2008). PMID: 18849306 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [34]
Kahaly GJ. “Management of Graves Thyroidal and Extrathyroidal Disease: An Update.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32929476 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [35]
Kim SM, Ryu V, Miyashita S et al.. “Thyrotropin, Hyperthyroidism, and Bone Mass.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34318885 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae - [36]
Villagelin D, Cooper DS, Burch HB. “A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38577717 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [37]
Biscarini F, Masetti G, Muller I et al.. “Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36683389 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification - [38]
Bezin J, Gouverneur A, Pénichon M et al.. “GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.” Diabetes care (2023). PMID: 36356111 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [39]
Xiang P, Latif R, Davies TF. “The Thyrotropin Receptor Antibody Reactome Determines Thyroid and Retro-orbital Responsiveness.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40654270 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [40]
Daniels GH, Ross DS. “Radioactive Iodine: A Living History.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37307104 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [41]
Bao Y, Kim D, Cho YH et al.. “Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37624749 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [42]
Sawin CT, Cooper DS. “The Origin of Antithyroid Drugs.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37594736 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [43]
Davies TF, Yin X, Latif R. “The genetics of the thyroid stimulating hormone receptor: history and relevance.” Thyroid : official journal of the American Thyroid Association (2010). PMID: 20578897 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [44]
Hébrant A, van Staveren WC, Maenhaut C et al.. “Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations.” European journal of endocrinology (2010). PMID: 20926595 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [45]
Burch HB, Cooper DS. “ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later.” European journal of endocrinology (2018). PMID: 30320502 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Prognosis, Natural History, Special Populations and Prevention - [46]
Biondi B. “Mechanisms in endocrinology: Heart failure and thyroid dysfunction.” European journal of endocrinology (2012). PMID: 22956554 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [47]
Lane LC, Cheetham TD, Razvi S et al.. “Expansion of the immature B lymphocyte compartment in Graves' disease.” European journal of endocrinology (2023). PMID: 37536284 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [48]
Wiersinga WM, Poppe KG, Effraimidis G. “Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis.” The lancet. Diabetes & endocrinology (2023). PMID: 36848916 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [49]
Wiersinga WM, Eckstein AK, Žarković M. “Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.” The lancet. Diabetes & endocrinology (2025). PMID: 40324443 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [50]
Wiersinga WM. “Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.” The lancet. Diabetes & endocrinology (2016). PMID: 27346786 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [51]
De Leo S, Pearce EN. “Autoimmune thyroid disease during pregnancy.” The lancet. Diabetes & endocrinology (2017). PMID: 29246752 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [52]
Chaker L, Cooper DS, Walsh JP et al.. “Hyperthyroidism.” Lancet (London, England) (2024). PMID: 38278171 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [53]
Robert M, Kotecki N, Gomez-Roca C et al.. “A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42034003 ↗
L4TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [54]
Lane LC, Cheetham TD, Perros P et al.. “New Therapeutic Horizons for Graves' Hyperthyroidism.” Endocrine reviews (2020). PMID: 32845332 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [55]
Liu ZW, Masterson L, Fish B et al.. “Thyroid surgery for Graves' disease and Graves' ophthalmopathy.” The Cochrane database of systematic reviews (2015). PMID: 26606533 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [56]
Park JY, Yoo SW, Kim SS et al.. “Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 41993975 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [57]
Kahaly GJ, Wolf J, Luffy M et al.. “Euthyroidism and Long-Term Remission of Graves' Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 41684304 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [58]
Teliti M, Gallo M, Costa P et al.. “Management of alemtuzumab-induced Graves' disease in pregnancy: a case report and literature review.” Frontiers in immunology (2025). PMID: 41607779 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [59]
Ilmer S, Salemi P. “Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease.” Frontiers in endocrinology (2026). PMID: 41585809 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [60]
Vardarli I, Tan S, Brandenburg T et al.. “Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37967245 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors - [61]
Ross DS, Burch HB, Cooper DS et al.. “2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 27521067 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [62]
Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F et al.. “The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24423323 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [63]
Roa Dueñas OH, Van der Burgh AC, Ittermann T et al.. “Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35137143 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [64]
Sheehan PM, Nankervis A, Araujo Júnior E et al.. “Maternal Thyroid Disease and Preterm Birth: Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26383905 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [65]
Osinga JAJ, Liu Y, Männistö T et al.. “Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38546971 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [66]
Bervini S, Trelle S, Kopp P et al.. “Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature.” Thyroid : official journal of the American Thyroid Association (2021). PMID: 33327840 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [67]
Roy A, Laszkowska M, Sundström J et al.. “Prevalence of Celiac Disease in Patients with Autoimmune Thyroid Disease: A Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2016). PMID: 27256300 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [68]
De Herdt C, Philipse E, De Block C. “ENDOCRINE TUMOURS: Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases.” European journal of endocrinology (2021). PMID: 34132199 ↗
L4SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [69]
Alwan H, Villoz F, Feller M et al.. “Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies.” European journal of endocrinology (2022). PMID: 36070417 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [70]
Struja T, Fehlberg H, Kutz A et al.. “Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis.” European journal of endocrinology (2016). PMID: 27780830 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [71]
Nederstigt C, Uitbeijerse BS, Janssen LGM et al.. “Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis.” European journal of endocrinology (2019). PMID: 30508413 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [72]
Osinga JAJ, Derakhshan A, Karachaliou M et al.. “Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis.” The lancet. Diabetes & endocrinology (2025). PMID: 40609565 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [73]
Kitahara CM, Slettebø Daltveit D, Ekbom A et al.. “Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study.” The lancet. Diabetes & endocrinology (2020). PMID: 33347809 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [74]
Kopp PA, Giordani I, Feldt-Rasmussen U et al.. “Approach to the patient with thyroid storm.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41655224 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [75]
Bartalena L, Smith TJ. “Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39787151 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [76]
Mäkimattila S, Harjutsalo V, Forsblom C et al.. “Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study.” Diabetes care (2020). PMID: 32139386 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [77]
Kim HJ, McLeod DSA. “Subclinical Hyperthyroidism and Cardiovascular Disease.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 39283826 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [78]
Li Y, Teng D, Ba J et al.. “Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China.” Thyroid : official journal of the American Thyroid Association (2020). PMID: 32075540 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors - [79]
Abraham-Nordling M, Byström K, Törring O et al.. “Incidence of hyperthyroidism in Sweden.” European journal of endocrinology (2011). PMID: 21908653 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [80]
Zimmermann MB, Boelaert K. “Iodine deficiency and thyroid disorders.” The lancet. Diabetes & endocrinology (2015). PMID: 25591468 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors - [81]
van Atteveld JE, de Winter DTC, Pluimakers VG et al.. “Risk and determinants of low and very low bone mineral density and fractures in a national cohort of Dutch adult childhood cancer survivors (DCCSS-LATER): a cross-sectional study.” The lancet. Diabetes & endocrinology (2022). PMID: 36513116 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [82]
Bahn RS. “Graves' ophthalmopathy.” The New England journal of medicine (2010). PMID: 20181974 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation - [83]
De Leo S, Lee SY, Braverman LE. “Hyperthyroidism.” Lancet (London, England) (2016). PMID: 27038492 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [84]
Franklyn JA, Boelaert K. “Thyrotoxicosis.” Lancet (London, England) (2012). PMID: 22394559 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [85]
Shine B, McKnight RF, Leaver L et al.. “Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data.” Lancet (London, England) (2015). PMID: 26003379 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [86]
Hemminki K, Li X, Sundquist J et al.. “Familial association between type 1 diabetes and other autoimmune and related diseases.” Diabetologia (2009). PMID: 19543881 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [87]
Wu KP, Luo XQ, Tan PX et al.. “Incidence and spectrum of immune-related adverse events in nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors.” Med (New York, N.Y.) (2026). PMID: 41653927 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [88]
Sohn SY, Inoue K, Rhee CM et al.. “Risks of Iodine Excess.” Endocrine reviews (2024). PMID: 38870258 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [89]
Abraham P, Avenell A, McGeoch SC et al.. “Antithyroid drug regimen for treating Graves' hyperthyroidism.” The Cochrane database of systematic reviews (2010). PMID: 20091544 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [90]
Zen XX, Yuan Y, Liu Y et al.. “Chinese herbal medicines for hyperthyroidism.” The Cochrane database of systematic reviews (2007). PMID: 17443591 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [91]
Ursem SR, Noordam R, van den Berg JM et al.. “Subclinical Hyperthyroidism, Cardiovascular Disease and All-Cause Mortality: Insights from a Large Dutch Primary Care Cohort Study.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42100953 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [92]
Kornerup LS, Kraglund F, Vilstrup H et al.. “Risk and prognosis of HCC in patients with thyroid disease: A nationwide cohort study.” Hepatology communications (2025). PMID: 41961637 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [93]
Jensen A, Nøhr B, Christensen J et al.. “Impact of hypothyroidism and hyperthyroidism on endometrial cancer incidence: results from a large population-based cohort study.” European journal of epidemiology (2026). PMID: 41879965 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors - [94]
Majidi A, Rinaldi S, Truong T et al.. “Pre-diagnosis thyroid dysfunction and ovarian cancer risk and survival: a prospective cohort study.” Journal of the National Cancer Institute (2026). PMID: 41706832 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [95]
Lou X, Jiang B, Huang Y et al.. “Sleep patterns, depression, and incident thyroid diseases: a large cohort study of 371,627 United Kingdom biobank participants.” BMC public health (2026). PMID: 41645168 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors - [96]
Markovic V, Eterovic D. “Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17609305 ↗
L2RCTCited in: Clinical Presentation - [97]
Scappaticcio L, Longo M, Maiorino MI et al.. “Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2021). PMID: 33327837 ↗
L1SR_OBSCited in: Clinical Presentation - [98]
Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗
L5CASE_REPORTCited in: Clinical Presentation - [99]
Law JH, Dean DS, Scheithauer B et al.. “Symptomatic amyloid goiters: report of five cases.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23544771 ↗
L4CASE_REPORTCited in: Clinical Presentation - [100]
Regelmann MO, Miloh T, Arnon R et al.. “Graves' disease presenting with severe cholestasis.” Thyroid : official journal of the American Thyroid Association (2012). PMID: 22458973 ↗
L4CASE_REPORTCited in: Clinical Presentation - [101]
Diazzi C, Brigante G, Rossi G et al.. “Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis.” Thyroid : official journal of the American Thyroid Association (2012). PMID: 22313427 ↗
L4CASE_REPORTCited in: Clinical Presentation - [102]
Hamon B, Hamon P, Bovier-Lapierre M et al.. “A child with resistance to thyroid hormone without thyroid hormone receptor gene mutation: a 20-year follow-up.” Thyroid : official journal of the American Thyroid Association (2008). PMID: 18302516 ↗
L4CASE_REPORTCited in: Clinical Presentation - [103]
Noh KW, Seon CS, Choi JW et al.. “Thyroid storm and reversible thyrotoxic cardiomyopathy after ingestion of seafood stew thought to contain marine neurotoxin.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21563915 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [104]
Chawla R, Alden TD, Bizhanova A et al.. “Squamosal Suture Craniosynostosis Due to Hyperthyroidism Caused by an Activating Thyrotropin Receptor Mutation (T632I).” Thyroid : official journal of the American Thyroid Association (2015). PMID: 26114856 ↗
L4CASE_REPORTCited in: Clinical Presentation - [105]
Peng R, Xie P, Jin Z et al.. “Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39715350 ↗
L2OTHERCited in: Clinical Presentation - [106]
Kung AW. “Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16608889 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [107]
Muir CA, Clifton-Bligh RJ, Long GV et al.. “Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33878162 ↗
L2OTHERCited in: Clinical Presentation - [108]
Graf H. “Recombinant human TSH and radioactive iodine therapy in the management of benign multinodular goiter.” European journal of endocrinology (2014). PMID: 25189867 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [109]
Shiang JC, Cheng CJ, Tsai MK et al.. “Therapeutic analysis in Chinese patients with thyrotoxic periodic paralysis over 6 years.” European journal of endocrinology (2009). PMID: 19755408 ↗
L2OTHERCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [110]
Chang CC, Cheng CJ, Sung CC et al.. “A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants.” European journal of endocrinology (2013). PMID: 23939916 ↗
L2OTHERCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [111]
Maioli M, Pes GM, Delitala G et al.. “Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults.” European journal of endocrinology (2010). PMID: 20603341 ↗
L2OTHERCited in: Clinical Presentation - [112]
Bandeira-Echtler E, Bergerhoff K, Richter B. “Levothyroxine or minimally invasive therapies for benign thyroid nodules.” The Cochrane database of systematic reviews (2014). PMID: 24941398 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [113]
Kopanos S, Knappe UJ, Moeller AS et al.. “Delay in Diagnosis of Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: Clinical and Endocrinological Profiles from a Retrospective Cohort Study.” Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2025). PMID: 41338539 ↗
L4COHORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [114]
Pan D, Ding S, Fang S et al.. “Case Report: Hyperthyroidism in a patient with spotty skin pigmentation and atrial myxoma (Carney complex): coincidence, association or cause?” Frontiers in cardiovascular medicine (2026). PMID: 41982221 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [115]
Peng G, Lei X, Leng W et al.. “Lugol's solution for preoperative management of a TSH/GH-secreting pituitary adenoma with suboptimal response to octreotide: a case report.” Frontiers in endocrinology (2026). PMID: 41625237 ↗
L4CASE_REPORTCited in: Clinical Presentation - [116]
Qian Le Boh GV, Chin HL, Zhang YC et al.. “McCune-Albright Syndrome as a Rare Cause of Fanconi Syndrome and Kidney Failure: A Case Report and Literature Review.” Kidney medicine (2025). PMID: 41510005 ↗
L4CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [117]
Skrzypiec-Spring M, Kuliczkowska-Płaksej J, Szeląg A et al.. “Post-COVID-19 subacute painless thyroiditis: a case report in an anabolic androgenic steroid user.” BMC infectious diseases (2025). PMID: 41366311 ↗
L4CASE_REPORTCited in: Clinical Presentation - [118]
Qiu Q, Li F, Zhong R et al.. “Case Report: Acute inferior myocardial infarction and third-degree atrioventricular block in a patient with hyperthyroidism.” Frontiers in cardiovascular medicine (2025). PMID: 41311507 ↗
L4CASE_REPORTCited in: Clinical Presentation - [119]
De Groot L, Abalovich M, Alexander EK et al.. “Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22869843 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [120]
Bahn Chair RS, Burch HB, Cooper DS et al.. “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21510801 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [121]
Grove-Laugesen D, Ebbehoj E, Watt T et al.. “Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37218433 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [122]
Floriani C, Feller M, Aubert CE et al.. “Thyroid Dysfunction and Anemia: A Prospective Cohort Study and a Systematic Review.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 29631476 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [123]
Sun L, Goh HJ, Verma S et al.. “Metabolic effects of brown fat in transitioning from hyperthyroidism to euthyroidism.” European journal of endocrinology (2021). PMID: 34342595 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [124]
Abraham-Nordling M, Lönn S, Wallin G et al.. “Hyperthyroidism and suicide: a retrospective cohort study in Sweden.” European journal of endocrinology (2009). PMID: 19131505 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae - [125]
Dekkers OM, Horváth-Puhó E, Cannegieter SC et al.. “Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study.” European journal of endocrinology (2016). PMID: 27697972 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [126]
Derakhshan A, Peeters RP, Taylor PN et al.. “Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis.” The lancet. Diabetes & endocrinology (2020). PMID: 32445737 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [127]
Lee SY, Pearce EN. “Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33349844 ↗
L5CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [128]
Roa Dueñas OH, Hofman A, Luik AI et al.. “The Cross-sectional and Longitudinal Association Between Thyroid Function and Depression: A Population-Based Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37855318 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [129]
Osinga JAJ, Derakhshan A, Feldt-Rasmussen U et al.. “TSH and FT4 Reference Interval Recommendations and Prevalence of Gestational Thyroid Dysfunction: Quantification of Current Diagnostic Approaches.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37740543 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [130]
Burch HB, Perros P, Bednarczuk T et al.. “Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 36480280 ↗
L1OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [131]
Jasim S, Papaleontiou M. “Considerations in the Diagnosis and Management of Thyroid Dysfunction in Older Adults.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40376729 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [132]
Ylli D, Soldin SJ, Stolze B et al.. “Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin.” Thyroid : official journal of the American Thyroid Association (2021). PMID: 34042535 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [133]
Azizi F, Amouzegar A. “Management of hyperthyroidism during pregnancy and lactation.” European journal of endocrinology (2011). PMID: 21389085 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [134]
Boelaert K, Visser WE, Taylor PN et al.. “ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism.” European journal of endocrinology (2020). PMID: 32438340 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [135]
Brusca N, Virili C, Cellini M et al.. “Early detection of biochemically occult autonomous thyroid nodules.” European journal of endocrinology (2016). PMID: 27647872 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [136]
Cooper DS, Laurberg P. “Hyperthyroidism in pregnancy.” The lancet. Diabetes & endocrinology (2013). PMID: 24622372 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [137]
Johnson MB, Hattersley AT, Flanagan SE. “Monogenic autoimmune diseases of the endocrine system.” The lancet. Diabetes & endocrinology (2016). PMID: 27474216 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [138]
Ma C, Xie J, Wang H et al.. “Radioiodine therapy versus antithyroid medications for Graves' disease.” The Cochrane database of systematic reviews (2016). PMID: 26891370 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [139]
Spencer L, Bubner T, Bain E et al.. “Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health.” The Cochrane database of systematic reviews (2015). PMID: 26387772 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [140]
Peluso A, Aljawfi O, Anderson KM et al.. “Health care utilization before and after COVID-19 diagnosis: a multidisease matched-cohort study by sociodemographic factors.” BMC health services research (2026). PMID: 42343378 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [141]
Xing Y, Wang J, Li X et al.. “Behind the mask of relapsing bimodal encephalitis: herpesvirus 7 and Epstein-Barr virus associated with Hashimoto's encephalopathy: a case report.” Frontiers in immunology (2026). PMID: 42292462 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [142]
Ke Y, Wu Y, Chong Y. “Case Report: Hyperthyroidism induced liver failure with Wolff-Parkinson-White syndrome.” Frontiers in medicine (2026). PMID: 41970404 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [143]
Oron T, Yackobovitch-Gavan M, Lazar L et al.. “Trends in Management and Outcomes of Pediatric Hyperthyroidism Over Two Decades.” Thyroid : official journal of the American Thyroid Association (2026). PMID: 42347684 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [144]
Ahmed I, Sarah C, Ryan Y et al.. “Central tibia marrow density is associated with incident fractures among postmenopausal females.” Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2026). PMID: 42261666 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [145]
Luo Y, Yao G, Song C et al.. “Thyroid diseases and risk of peripheral neuropathy in a large population-based cohort: evidence from the UK Biobank.” Frontiers in endocrinology (2026). PMID: 42238236 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [146]
Sazumi Y, Soejima Y, Otsuka Y et al.. “Behavior of serum thyroglobulin in relation to thyroid function under low-thyrotropin conditions in general practice.” Frontiers in endocrinology (2026). PMID: 42222078 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [147]
Alves Junior JM, Bernardo W, Villagelin D. “Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review With Meta-analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 39076015 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [148]
Kotwal A, Cortes T, Genere N et al.. “Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32954428 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [149]
Yang LB, Jiang DQ, Qi WB et al.. “Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies.” European journal of endocrinology (2012). PMID: 22535645 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [150]
Bogazzi F, Bartalena L, Martino E. “Approach to the patient with amiodarone-induced thyrotoxicosis.” The Journal of clinical endocrinology and metabolism (2010). PMID: 20525904 ↗
L5CASE_REPORTCited in: Severity, Staging and Risk Stratification - [151]
Griffith ML, Bischoff LA, Baum HBA. “Approach to the Patient With Thyrotoxicosis Using Telemedicine.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32525973 ↗
L4CASE_REPORTCited in: Severity, Staging and Risk Stratification - [152]
Thomas D, Moisidis A, Tsiakalos A et al.. “Antithyroid drug-induced aplastic anemia.” Thyroid : official journal of the American Thyroid Association (2008). PMID: 18816182 ↗
L4CASE_REPORTCited in: Severity, Staging and Risk Stratification - [153]
Wolff EF, Hughes M, Merino MJ et al.. “Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.” Thyroid : official journal of the American Thyroid Association (2010). PMID: 20718682 ↗
L5CASE_REPORTCited in: Severity, Staging and Risk Stratification - [154]
Profilo MA, Sisti E, Marcocci C et al.. “Thyroid volume and severity of Graves' orbitopathy.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23088654 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification - [155]
Li GH, Tang CM, Cheung CL. “COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 35734897 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [156]
Kim N, Gu JY, Yoo HJ et al.. “Contact system activation and high thrombin generation in hyperthyroidism.” European journal of endocrinology (2017). PMID: 28137735 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification - [157]
Léger J, Carel JC. “MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease.” European journal of endocrinology (2017). PMID: 28381452 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification - [158]
Vos XG, Smit N, Endert E et al.. “Age and stress as determinants of the severity of hyperthyroidism caused by Graves' disease in newly diagnosed patients.” European journal of endocrinology (2008). PMID: 18974230 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification - [159]
Kostadinov N, Kirovakov Z, Penchev P. “Efficacy of Selenium Supplementation in Graves' Orbitopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.” Journal of clinical medicine (2026). PMID: 42355878 ↗
L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification - [160]
Zhang J, Chen Y, Huang G et al.. “Association between maternal thyroid function and adverse outcomes of pregnant women and offspring: evidence from an umbrella review.” BMC pregnancy and childbirth (2026). PMID: 41963840 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [161]
He GS, Ling Chia JL, Hao TT et al.. “Outcomes of Surgery Versus Radioactive Iodine as Definitive Therapy in Pediatric Graves' Disease: A Systematic Review and Meta-Analysis of Cohort Studies.” World journal of surgery (2026). PMID: 41665506 ↗
L2SR_OBSCited in: Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [162]
Dong Y, Li Y, Peng X et al.. “Immune checkpoint inhibitors-induced thyroid dysfunction improves the prognosis of patients with lung cancer: a meta-analysis and systematic review.” Frontiers in endocrinology (2026). PMID: 41641031 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [163]
Wang QH, Ye JJ, Chen ZY et al.. “Current risk factors for male infertility and semen parameters: an umbrella review of systematic reviews and meta-analyses.” Asian journal of andrology (2026). PMID: 41527944 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [164]
Kłosowicz M, Urbańczuk M, Burbelka A et al.. “Impact of Thyroid Hormone Imbalance on Electrocardiographic Parameters: Systematic Review and Meta-Analysis.” Journal of clinical medicine (2025). PMID: 41464657 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [165]
Napoli R, Guardasole V, Angelini V et al.. “Acute effects of triiodothyronine on endothelial function in human subjects.” The Journal of clinical endocrinology and metabolism (2006). PMID: 17047021 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [166]
Mannavola D, Coco P, Vannucchi G et al.. “A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17595247 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies - [167]
Kaptein EM, Beale E, Chan LS. “Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19737920 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [168]
Fung MHM, Luk Y, Yuen KKW et al.. “The Two-Year Results of Using Radiofrequency Ablation as a Novel Treatment for Persistent or Relapsed Graves' Disease: A Prospective Study.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38836419 ↗
L4TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [169]
Schultz M, Kistorp C, Langdahl B et al.. “N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism.” Thyroid : official journal of the American Thyroid Association (2007). PMID: 17381357 ↗
L4TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies - [170]
Pecere A, Caputo M, Sarro A et al.. “Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32813014 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies - [171]
Guo JY, Chang CL, Chen CC. “Association Between Thionamides and Acute Pancreatitis: A Case-Control Study.” Thyroid : official journal of the American Thyroid Association (2020). PMID: 32380933 ↗
L3CASE_CONTROLCited in: Acute Management and Endocrine Emergencies - [172]
Chee YJ, Liew H, Hoi WH et al.. “SARS-CoV-2 mRNA Vaccination and Graves' Disease: A Report of 12 Cases and Review of the Literature.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35235663 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [173]
Trapp CM, Elder RW, Gerken AT et al.. “Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22622024 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [174]
Calderon A, Aguilera M, Drinnon AR et al.. “Therapeutic Plasma Exchange in Severe Thyrotoxicosis: Clinical Observations From a Case Series.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41557149 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [175]
Patel R, Peterson G, Rohatgi A et al.. “Hyperthyroidism-associated coronary vasospasm with myocardial infarction and subsequent euthyroid angina.” Thyroid : official journal of the American Thyroid Association (2008). PMID: 18279027 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [176]
Chiniwala NU, Woolf PD, Bruno CP et al.. “Thyroid storm caused by a partial hydatidiform mole.” Thyroid : official journal of the American Thyroid Association (2008). PMID: 18352822 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [177]
Fazendin J, Zmijewski P, Allahwasaya A et al.. “Surgical Treatment of Hyperthyroidism Can Be Performed Safely Before a Euthyroid State is Achieved.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37253173 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [178]
Bai X, Chen X, Wu X et al.. “Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase.” European journal of endocrinology (2020). PMID: 31648184 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies - [179]
Botella-Carretero JI, Alvarez-Blasco F, San Millán JL et al.. “Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women.” European journal of endocrinology (2007). PMID: 17468189 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [180]
Qiu Y, Huang Z, Ma T et al.. “Clinical heterogeneity and immunotherapy outcomes in anti-GAD65 antibody-associated autoimmune encephalitis: a retrospective study.” Therapeutic advances in neurological disorders (2026). PMID: 42293573 ↗
L4COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [181]
Deng C, Inoue K, Saechao C et al.. “Maternal Thyroid Diseases, Medication Use and Childhood Cancer Risks in Offspring: A Population-Based Cohort Study in Denmark.” International journal of cancer (2026). PMID: 42260983 ↗
L3COHORTCited in: Acute Management and Endocrine Emergencies - [182]
Gao X, Chang W, Sun K et al.. “Lithium carbonate bridging and outcomes of radioiodine therapy in severe Graves' disease: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42181214 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [183]
Hommos L, Gohil H, Rob M et al.. “Long-Term Thyroid Complications Post-COVID-19: A Systematic Review.” Microorganisms (2026). PMID: 41900303 ↗
L2SR_OBSCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [184]
Newman C, Saqlain M, Mohammed IA et al.. “Iopanoic acid rapidly restores euthyroidism in refractory thyrotoxicosis pre-thyroidectomy: a retrospective study.” European thyroid journal (2026). PMID: 41738978 ↗
L4COHORTCited in: Acute Management and Endocrine Emergencies - [185]
Brigante G, Santi D, Boselli G et al.. “Randomized double-blind placebo-controlled trial on levothyroxine and liothyronine combination therapy in totally thyroidectomized subjects: the LEVOLIO study.” European journal of endocrinology (2024). PMID: 38124252 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [186]
Brandt F, Green A, Hegedüs L et al.. “A critical review and meta-analysis of the association between overt hyperthyroidism and mortality.” European journal of endocrinology (2011). PMID: 21724839 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [187]
de Rooij A, Vandenbroucke JP, Smit JW et al.. “Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis.” European journal of endocrinology (2009). PMID: 19671708 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [188]
Groeneweg S, Peeters RP, Moran C et al.. “Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.” The lancet. Diabetes & endocrinology (2019). PMID: 31377265 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [189]
Toloza FJK, Derakhshan A, Männistö T et al.. “Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis.” The lancet. Diabetes & endocrinology (2022). PMID: 35255260 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [190]
Korevaar TI, Muetzel R, Medici M et al.. “Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study.” The lancet. Diabetes & endocrinology (2015). PMID: 26497402 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [191]
Kim BW. “Does Radioactive Iodine Therapy for Hyperthyroidism Cause Cancer?” The Journal of clinical endocrinology and metabolism (2022). PMID: 34555150 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [192]
Gillard P, Huurman V, Van der Auwera B et al.. “Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies.” Diabetes care (2009). PMID: 19549735 ↗
L4OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [193]
Chng CL, Goh GBB, Yen PM. “Metabolic and Functional Cross Talk Between the Thyroid and Liver.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40420529 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [194]
Laurberg P, Andersen SL. “ENDOCRINOLOGY IN PREGNANCY: Pregnancy and the incidence, diagnosing and therapy of Graves' disease.” European journal of endocrinology (2016). PMID: 27280373 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [195]
Earl R, Crowther CA, Middleton P. “Interventions for hyperthyroidism pre-pregnancy and during pregnancy.” The Cochrane database of systematic reviews (2013). PMID: 24249524 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [196]
Earl R, Crowther CA, Middleton P. “Interventions for preventing and treating hyperthyroidism in pregnancy.” The Cochrane database of systematic reviews (2010). PMID: 20824882 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [197]
Jin H, Luo J, Wu M et al.. “Resolved hyperthyroidism before IVF is not associated with improved cumulative live birth rates: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42318210 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [198]
Castro-Diaz SD, Castro-Diaz JD, Ruiz-Vargas VM et al.. “Prevalence and incidence of hypothyroidism and hyperthyroidism in patients with chronic kidney disease on dialysis: a systematic review and meta-analysis.” BMC nephrology (2026). PMID: 42015061 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [199]
Yang Y, Zhong G. “Prevalence and risk factors for postoperative atrial fibrillation following pulmonary resection: a systematic review and meta-analysis.” Journal of cardiothoracic surgery (2026). PMID: 42001140 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [200]
Yin P, Wu J, Zhao H et al.. “Early Transient Hypothyroidism Is Associated With Long-Term Outcomes of 131I Treatment in Graves' Disease: A Retrospective Cohort Study.” Clinical endocrinology (2026). PMID: 42098592 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [201]
. “Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.” Ontario health technology assessment series (2026). PMID: 42311839 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [202]
Medici M, Direk N, Visser WE et al.. “Thyroid function within the normal range and the risk of depression: a population-based cohort study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24564323 ↗
L2COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [203]
Tamada D, Onodera T, Kitamura T et al.. “Hyperthyroidism due to thyroid-stimulating hormone secretion after surgery for Cushing's syndrome: a novel cause of the syndrome of inappropriate secretion of thyroid-stimulating hormone.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23671315 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [204]
Ma S, Hu M, Yang H et al.. “Periodic Paralysis as a New Phenotype of Resistance to Thyroid Hormone Syndrome in a Chinese Male Adult.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26652765 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [205]
Sinkó R, Mohácsik P, Kővári D et al.. “Different Hypothalamic Mechanisms Control Decreased Circulating Thyroid Hormone Levels in Infection and Fasting-Induced Non-Thyroidal Illness Syndrome in Male Thyroid Hormone Action Indicator Mice.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 36322711 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [206]
Weiss RE, Lemos JRN, Dumitrescu AM et al.. “Combined Levothyroxine and Propylthiouracil Treatment in Children with Monocarboxylate Transporter 8 Deficiency: A Multicenter Case Series of 12 Patients.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 39283825 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [207]
Nwosu BU, Gourgiotis L, Gershengorn MC et al.. “A novel activating mutation in transmembrane helix 6 of the thyrotropin receptor as cause of hereditary nonautoimmune hyperthyroidism.” Thyroid : official journal of the American Thyroid Association (2006). PMID: 16756474 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [208]
Völzke H, Schwahn C, Wallaschofski H et al.. “Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship?” The Journal of clinical endocrinology and metabolism (2007). PMID: 17473067 ↗
L2REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [209]
Simon M, Rigou A, Le Moal J et al.. “Epidemiology of Childhood Hyperthyroidism in France: A Nationwide Population-Based Study.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29846622 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [210]
Muller I, Willis M, Healy S et al.. “Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years.” Thyroid : official journal of the American Thyroid Association (2018). PMID: 30351224 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [211]
Musolino A, Grifoni GFA, Rodolfi S et al.. “Variable Diagnoses in Cases Referred for Discordant Thyroid Function Tests: Focus on Lymphoproliferative Disorders.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40737226 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [212]
Franchini M, Lippi G, Manzato F et al.. “Hemostatic abnormalities in endocrine and metabolic disorders.” European journal of endocrinology (2009). PMID: 19934268 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [213]
Lebbink CA, Bresters D, Tersteeg JPB et al.. “Changes in thyroid function parameters 3 months after allogeneic and autologous hematopoietic stem cell transplantation in children.” European journal of endocrinology (2023). PMID: 37232272 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [214]
Vargas F, Moreno JM, Wangensteen R et al.. “The endocrine system in chronic nitric oxide deficiency.” European journal of endocrinology (2007). PMID: 17218720 ↗
L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [215]
Forestier E, Vinzio S, Sapin R et al.. “Increased reverse triiodothyronine is associated with shorter survival in independently-living elderly: the Alsanut study.” European journal of endocrinology (2008). PMID: 19001060 ↗
L2OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [216]
Medici M, Visser WE, Visser TJ et al.. “Genetic determination of the hypothalamic-pituitary-thyroid axis: where do we stand?” Endocrine reviews (2015). PMID: 25751422 ↗
L5REVIEW_NARRATIVECited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [217]
Peng CC, Spiegel BR, Flynn D et al.. “Mortality Risks Associated with Antithyroid Drugs, Radioactive Iodine, and Surgery for Hyperthyroidism: A Systematic Review and Network Meta-Analysis.” Thyroid : official journal of the American Thyroid Association (2025). PMID: 40891035 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae - [218]
Haentjens P, Van Meerhaeghe A, Poppe K et al.. “Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies.” European journal of endocrinology (2008). PMID: 18511471 ↗
L1SR_OBSCited in: Complications and Long-term Sequelae - [219]
Cheng Y, Hu H, Li W et al.. “Chronic Kidney Disease and Thyroid Hormones.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39657910 ↗
L3OTHERCited in: Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [220]
Baretella O, Blum MR, Abolhassani N et al.. “Associations Between Subclinical Thyroid Dysfunction and Cardiovascular Risk Factors According to Age and Sex.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39667018 ↗
L2OTHERCited in: Complications and Long-term Sequelae - [221]
Ponto KA, Zang S, Kahaly GJ. “The tale of radioiodine and Graves' orbitopathy.” Thyroid : official journal of the American Thyroid Association (2010). PMID: 20578895 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [222]
Khamisi S, Udumyan R, Sjölin G et al.. “Fracture Incidence in Graves' Disease: A Population-Based Study.” Thyroid : official journal of the American Thyroid Association (2023). PMID: 37725590 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [223]
Biondi B. “How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism?” European journal of endocrinology (2012). PMID: 22802423 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [224]
Chavassieux P, Seeman E, Delmas PD. “Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.” Endocrine reviews (2006). PMID: 17200084 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [225]
Kucukay F, Tuna HS. “Thyroid Artery Embolization for Benign Symptomatic Multinodular Euthyroid Goiter: 24-Month Outcomes from a Single-Center Retrospective Study.” Journal of vascular and interventional radiology : JVIR (2026). PMID: 42217823 ↗
L4COHORTCited in: Complications and Long-term Sequelae - [226]
Yamashita H, Yoshimoto K, Okamura M et al.. “Perioperative endocrine dynamics in euthyroid versus hyperthyroid patients with Graves' disease undergoing total thyroidectomy: a prospective cohort study.” BMC surgery (2026). PMID: 41904519 ↗
L2COHORTCited in: Complications and Long-term Sequelae - [227]
Ünlü MT, Caliskan O, Çetinoğlu I et al.. “Preoperative Lugol's solution and surgical outcomes in Graves' disease: a single-center retrospective study.” Frontiers in surgery (2026). PMID: 41835246 ↗
L2COHORTCited in: Complications and Long-term Sequelae - [228]
Virgini VS, Wijsman LW, Rodondi N et al.. “Subclinical thyroid dysfunction and functional capacity among elderly.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23941540 ↗
L2RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [229]
Minassian C, Allen LA, Okosieme O et al.. “Preconception Management of Hyperthyroidism and Thyroid Status in Subsequent Pregnancy: A Population-Based Cohort Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37200150 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [230]
Effraimidis G, Strieder TG, Tijssen JG et al.. “Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study.” European journal of endocrinology (2010). PMID: 20956436 ↗
L3COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [231]
Salas-Lucia F. “Mapping Thyroid Hormone Action in the Human Brain.” Thyroid : official journal of the American Thyroid Association (2024). PMID: 38757586 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention - [232]
Yang X, Zhang C, Williamson C et al.. “Association of Maternal Thyroid Function with Gestational Hypercholanemia.” Thyroid : official journal of the American Thyroid Association (2021). PMID: 34941431 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention